A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years
Phase: PHASE3
Conditions: Respiratory Syncytial Virus Prevention
Sponsor: Janssen Vaccines & Prevention B.V.

CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
1
Status: Approved,Date: 26 November 2021
Janssen Vaccines & Prevention B.V.*
Clinical Protocol
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of
an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75Years
Protocol VAC18193RSV3003; Phase 3
Amendment 2
VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
* Janssen Vaccines & Prevention B.V. is a Janssen pharmaceutical company of Johnson & Johnson and is
hereafter referred to as the sponsor of the study. The sponsor is identified on the Contact Information page
that accompanies the protocol.
United States (US)sites of this study will be conducted under US Food & Drug Administration
Investigational New Drug (IND) regulations (21 CFR Part 312).
EudraCT NUMBER: 2021-002388-23
Status: 
Approved
Date: 
26 November 2021
Prepared by: 
Janssen Vaccines & Prevention B.V.
EDMS number: 
EDMS-RIM-330911, 3.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory
requirements.
Confidentiality Statement
The information provided herein contains Company trade secrets, commercial or financial information that the Company
customarily holds close and treats as confidential.  The information is being provided under the assurance that the recipient
will maintain the confidentiality of the information under applicable statutes, regulations, rules, protective orders or otherwise.
NCT05101486

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
2
Status: Approved,Date: 26 November 2021
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE
DOCUMENT HISTORY
Document 
Date
Amendment 2 
This document
Amendment 1 
23 September 2021
Original Protocol 
17 May 2021
Amendment 2 (This document)
Overall Rationale for the Amendment: In view of the slow rate of enrollment in the current
study, the following changes were made to the inclusion  and exclusion criteria to facilitate
enrollment: the upper age limit for inclusion was adapted from less than 65 years to 75 years
inclusive; a prior vaccination with a viral-vectored SARS-CoV-2 vaccine is allowed if
administered at least 6 months prior to randomization; and it was clarified that co-participation in
the observational phase of interventional studies can be allowed upon sponsor approval.
Emerging data from other ongoing clinical studies with the Ad26/protein preF RSV vaccine in
participants in the age range of 60 to 75 years show that there is no substantial impact of age on
vaccine-induced humoral immune responses, primary analysis pre-F ELISA antibody titers, and
vaccine safety between older adults of 60 to 75 years of age. Based on these data, the sponsor
considers an upper age limit of 75 years (inclusive) acceptable for this study.
Clinical studies with Janssen’s Ad26-vectored SARS-CoV-2 vaccine have not shown a clear
impact of baseline pre-existing Ad26 neutralizing antibodies on vaccine-induced responses. Based
on these data, the sponsor considers a prior vaccination with a viral-vectored SARS-CoV-2 vaccine
acceptable if administered at least 6 months prior to randomization. A minimal window of6
months has been chosen since humoral immune response data evaluating a potential interference
of the anti-vector responses with the vaccine-induced responses in consecutive dosing with viral-
vectored vaccines with different inserts are not available to date. During further development of
viral-vectored vaccines, data on potential interference will become available; at that point,the time
window may be adjusted for future immunogenicity trials. The standard dosing window for viral-
vectored SARS-CoV-2 vaccines in other Ad26.RSV.preF-based vaccine efficacy studies is 28
days and does not foresee an impact on safety.
Participants who participate in the observational phase of an interventional study at screening may
also be eligible for the current study since participation in the observational phase without product
administration will not adversely impact safety of the participants or have an impact on the
vaccine-induced immune response.
Furthermore, additional language referring to laboratory diagnostic tests for the follow-up and
assessment of potential adverse events of special interest (AESIs) was added. Clarifications were
made with regards to some exclusion criteria, the recording of medical history, and the solicited
and unsolicited AE assessments to be performed during phone call visits. Additionally, an

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
3
Status: Approved,Date: 26 November 2021
inconsistency concerning the timing of the primary analysis was corrected and a few minor updates
were made in alignment with the latest Janssen protocol template.
The changes made to the clinical protocol VAC18193RSV3003 as part of Protocol Amendment 2
are listed below, including the rationale of each change and a list of all applicable sections.
Changes made in previous protocol amendments are listed in Section 10.7 Appendix 7: Protocol
Amendment History.
Section Number 
and Name
Description of Change 
Brief Rationale
Title page 
1.1 Synopsis 
4.1 Overall Design  
5.1 Inclusion Criteria 
Inclusion Criterion 3 was amended to
expand the eligible age range from 60
to less than 65 years, to 60 to 75
years inclusive.
To facilitate enrollment
5.2 Exclusion Criteria 
Exclusion Criterion 10 was amended
to allow the use of viral-vectored
SARS-CoV-2 vaccines if
administered at least 6 months prior
to randomization.
To facilitate enrollment
5.2 Exclusion Criteria 
Footnote for Exclusion Criterion 13
was updated to allow participants who
participate in the observational phase
of interventional studies to be enrolled
in the study, if approved by the
sponsor or its delegate.
To facilitate enrollment
5.2 Exclusion Criteria 
A textual change was made to
Exclusion Criterion 1 to clarify that
participants with a history of
malignancy within 5 years before
screening, which is considered to
have minimal risk of recurrence per
investigator’s judgement, can be
enrolled.
Clarification
5.2 Exclusion Criteria 
Exclusion Criterion 7 was amended
to restrict the exclusion of
participants on treatment with
immunoglobulins to those
immunoglobulins expected to impact
the vaccine-induced immune
response.
Clarification
1.3 Schedule of Activities 
It was clarified that risk factors for
blood clotting events and
thrombocytopenia are to be collected
and documented as part of the
medical history at screening.
Clarification
1.3 Schedule of Activities 
It was clarified that the severity of
solicited and unsolicited AEs and the
occurrence of special reporting
situations are to be assessed also
during the phone call visits at 7 and
28 days post-vaccination,following
the recording period specified for
these events.
Clarification

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
4
Status: Approved,Date: 26 November 2021
Section Number
and Name
Description of Change 
Brief Rationale 
1.3 Schedule of Activities 
8.3.6.1 Thrombosis with 
Thrombocytopenia Syndrome 
Additional language referring to
laboratory diagnostic tests for the
assessment of potential AESIs was
added.
To facilitate and simplify the local
site management of follow-up
testings in the event of potential
AESIs.
9.4.1 General Considerations 
It was clarified that the primary
analysis will be performed when all
participants have completed the visit
28 days post-vaccination or
discontinued earlier.
Correction of an inconsistency
4.4 End of Study Definition  
8.3.1 Time Period and Frequency 
for Collecting AE,SAE,and 
AESI Information
8.3.3 Follow-up of AEs,SAEs
and AESIs
10.2.4 Special Reporting
Situations
10.2.6 PQC Handling
10.3.14 Study and Site Start and
Closure
10.5 Appendix 5: Study Conduct
During a Natural Disaster
A few minor updates were made in
alignment with the latest Janssen
protocol template
To align with the most recent
Janssen protocol template.
Throughout the protocol 
Minor grammatical, formatting, or
spelling changes were made.
Minor errors were noted

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
5
Status: Approved,Date: 26 November 2021
TABLE OF CONTENTS
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE ............................................................... 2
TABLE OF CONTENTS ............................................................................................................................... 5
LIST OF IN-TEXT TABLES AND FIGURES................................................................................................ 7
1. 
PROTOCOL SUMMARY..................................................................................................................... 8
1.1. 
Synopsis........................................................................................................................................... 8
1.2. 
Schema.......................................................................................................................................... 13
1.3. 
Schedule of Activities..................................................................................................................... 14
2. 
INTRODUCTION................................................................................................................................ 17
2.1. 
Study Rationale.............................................................................................................................. 17
2.2. 
Background .................................................................................................................................... 17
2.3. 
Benefit-Risk Assessment............................................................................................................... 19
2.3.1. 
Risks Related to Study Participation .......................................................................................... 19
2.3.2. 
Benefits of Study Participation.................................................................................................... 21
2.3.3. 
Benefit-Risk Assessment of Study Participation ........................................................................ 21
3. 
OBJECTIVES AND ENDPOINTS ..................................................................................................... 22
4. 
STUDY DESIGN ................................................................................................................................ 24
4.1. 
Overall Design................................................................................................................................ 24
4.2. 
Scientific Rationale for Study Design............................................................................................. 25
4.2.1. 
Study-Specific Ethical Design Considerations ........................................................................... 26
4.3. 
Justification for Dose...................................................................................................................... 26
4.4. 
End of Study Definition................................................................................................................... 27
5. 
STUDY POPULATION ...................................................................................................................... 27
5.1. 
Inclusion Criteria............................................................................................................................ 27
5.2. 
Exclusion Criteria........................................................................................................................... 28
5.3. 
Lifestyle Considerations................................................................................................................. 31
5.4. 
Screen Failures.............................................................................................................................. 31
5.5. 
Criteria for Temporarily Delaying Study Vaccine Administration ................................................... 32
6. 
STUDY VACCINE(S) AND CONCOMITANT THERAPY ................................................................. 32
6.1. 
Study Vaccine Administration ........................................................................................................ 32
6.2. 
Preparation/Handling/Storage/Accountability ................................................................................ 33
6.3. 
Measures to Minimize Bias: Randomization and Blinding............................................................. 34
6.4. 
Study Vaccination Compliance ...................................................................................................... 35
6.5. 
Dose Modification........................................................................................................................... 35
6.6. 
Continued Access to Study Vaccine After the End of the Study ................................................... 35
6.7. 
Treatment of Overdose .................................................................................................................. 35
6.8. 
Concomitant Therapy..................................................................................................................... 36
7. 
DISCONTINUATION OF STUDY VACCINATION AND PARTICIPANT
DISCONTINUATION/WITHDRAWAL............................................................................................... 37
7.1. 
Discontinuation of Study Vaccination............................................................................................. 37
7.2. 
Participant Discontinuation/Withdrawal From the Study................................................................ 37
7.2.1. 
Withdrawal From the Use of Research Samples ....................................................................... 38
7.3. 
Lost to Follow-up............................................................................................................................ 38
8. 
STUDY ASSESSMENTS AND PROCEDURES ............................................................................... 38
8.1. 
Immunogenicity Assessments ....................................................................................................... 40
8.2. 
Safety Assessments....................................................................................................................... 41
8.2.1. 
Physical Examinations................................................................................................................ 41

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
6
Status: Approved,Date: 26 November 2021
8.2.2. 
Vital Signs................................................................................................................................... 41
8.3. 
AEs, SAEs, AESIs and Other Safety Reporting ............................................................................ 41
8.3.1. 
Time Period and Frequency for Collecting AE, SAE, and AESI Information.............................. 42
8.3.2. 
Method of Detecting AEs, SAEs and AESIs............................................................................... 43
8.3.3. 
Follow-up of AEs, SAEs and AESIs ........................................................................................... 44
8.3.4. 
Regulatory Reporting Requirements for SAEs........................................................................... 44
8.3.5. 
Pregnancy................................................................................................................................... 44
8.3.6. 
Adverse Events of Special Interest............................................................................................. 45
8.3.6.1. 
Thrombosis with Thrombocytopenia Syndrome...................................................................... 45
8.4. 
Medical Resource Utilization.......................................................................................................... 47
9. 
STATISTICAL CONSIDERATIONS.................................................................................................. 47
9.1. 
Statistical Hypotheses.................................................................................................................... 47
9.2. 
Sample Size Determination ........................................................................................................... 47
9.3. 
Populations for Analysis Sets ........................................................................................................ 48
9.4. 
Statistical Analyses ........................................................................................................................ 48
9.4.1. 
General Considerations.............................................................................................................. 49
9.4.2. 
Participant Information................................................................................................................ 49
9.4.3. 
Immunogenicity Analyses........................................................................................................... 49
9.4.3.1. 
Primary Endpoints ................................................................................................................... 49
9.4.3.2. 
Secondary and Exploratory Endpoints .................................................................................... 50
9.4.4. 
Safety Analyses.......................................................................................................................... 50
9.5. 
Planned Analyses .......................................................................................................................... 51
10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS ............................ 52
10.1. 
Appendix 1: Abbreviations ............................................................................................................. 52
10.2. 
Appendix 2: AEs, SAEs, AESIs, PQCs, and Other Safety Reporting: Definitions and
Procedures for Recording, Evaluating, Follow-up, and Reporting................................................. 53
10.2.1. 
AE Definitions and Classifications.............................................................................................. 53
10.2.2. 
Attribution Definitions.................................................................................................................. 54
10.2.3. 
Severity Criteria.......................................................................................................................... 54
10.2.4. 
Special Reporting Situations ...................................................................................................... 55
10.2.5. 
Procedures ................................................................................................................................. 55
10.2.6. 
PQC Handling............................................................................................................................. 57
10.2.7. 
Contacting Sponsor Regarding Safety, Including Product Quality............................................. 57
10.3. 
Appendix 3: Regulatory, Ethical, and Study Oversight Considerations......................................... 58
10.3.1. 
Regulatory and Ethical Considerations ...................................................................................... 58
10.3.2. 
Financial Disclosure.................................................................................................................... 61
10.3.3. 
Informed Consent Process ......................................................................................................... 61
10.3.4. 
Data Protection........................................................................................................................... 62
10.3.5. 
Long-Term Retention of Samples for Additional Future Research ............................................ 63
10.3.6. 
Committees Structure................................................................................................................. 63
10.3.7. 
Publication Policy/Dissemination of Clinical Study Data............................................................ 63
10.3.8. 
DataQuality Assurance.............................................................................................................. 65
10.3.9. 
Case Report Form Completion................................................................................................... 65
10.3.10. Source Documents ..................................................................................................................... 65
10.3.11. Monitoring ................................................................................................................................... 66
10.3.12. On-Site Audits............................................................................................................................. 67
10.3.13. Record Retention........................................................................................................................ 67
10.3.14. Study and Site Start and Closure ............................................................................................... 68
10.4. 
Appendix 4: Toxicity Grading Scale............................................................................................... 69
10.5. 
Appendix 5: Study Conduct During a Natural Disaster.................................................................. 74
10.6. 
Appendix 6: Thrombotic Events to be Reported as Potential AESIs ............................................. 76
10.7. 
Appendix 7: Protocol Amendment History..................................................................................... 77
11. REFERENCES................................................................................................................................... 78

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
7
Status: Approved,Date: 26 November 2021
INVESTIGATOR AGREEMENT................................................................................................................. 80
LIST OF IN-TEXT TABLES AND FIGURES
TABLES
Table 1: 
Study Design............................................................................................................................. 10
Table 2: 
Study Design............................................................................................................................. 24
Table 3: 
Summary of Immunogenicity Assays (Humoral)...................................................................... 40
Table 4: 
Laboratory Tests That May Be Performed Upon Sponsor Request on Immunogenicity
Samples Collected on Day 1, 15, and/or 183 After Potential AESI Reporting ......................... 46
Table 5: 
Laboratory Tests That May Be Requested by the Sponsor to be Performed at the
Central Laboratory After Potential AESI Reporting .................................................................. 46
FIGURES
Figure 1: Schematic Overview of the Study............................................................................................. 13

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
8
Status: Approved,Date: 26 November 2021
1. 
PROTOCOL SUMMARY
1.1. 
Synopsis
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an
Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years
The respiratory syncytial virus (RSV) vaccine that will be investigated in this study, the Ad26/protein preF
RSV vaccine (VAC18193), is a combination of 2 vaccine components, administered as a single
intramuscular (IM) injection:
 Ad26.RSV.preF (JNJ-64400141), a replication-incompetent adenovirus serotype 26 (Ad26) containing
a DNA transgene that encodes the prefusion conformation-stabilized F protein (pre-F) derived from the
RSV A2 strain.
 RSV preF protein (JNJ-64213175), a recombinant pre-F protein derived from the RSV A2 strain.
The aim of this study is to demonstrate the non-inferiority in terms of humoral immune responses of
Ad26/protein preF RSV vaccine lots representing key stability indicating critical quality attributes (eg,
potency of Ad26.RSV.preF, purity of RSV preF protein) halfway (“intermediate shelf-life”) and at the end
of the intended shelf-life (“end of shelf-life”) in comparison to a non-aged Ad26/protein preF RSV vaccine
lot. Demonstrating non-inferior humoral immune responses of material at “intermediate shelf-life” and at
“end of shelf-life” to near release material will allow to infer efficacy throughout the vaccine shelf-life.
OBJECTIVES AND ENDPOINTS
Objectives 
Endpoints
Primary
 
To demonstrate non-inferiority in terms of 
humoral immune responses induced by 
Ad26.RSV.preF-based study vaccine lots 
representing the critical quality attributes
around the intermediate shelf-life to
Ad26.RSV.preF-based study vaccine lots
representing the critical quality attributes
near release.
 
pre-F enzyme-linked immunosorbent assay
(ELISA) antibody titers at 14 days after
vaccination.
 
If non-inferiority is demonstrated for the 
Ad26.RSV.preF-based study vaccine lots 
representing the critical quality attributes
around the intermediate shelf-life:
To demonstrate non-inferiority in terms of
humoral immune responses induced by
Ad26.RSV.preF-based study vaccine lots
representing the critical quality attributes
near the presumed end of shelf-life to
Ad26.RSV.preF-based study vaccine lots
representing the critical quality attributes
near release.
 
pre-F ELISA antibody titers at 14 days
after vaccination.
Secondary
 
To assess neutralizing antibody responses 
following vaccination  
 
Neutralizing antibody titers against RSV A2
strain at 14 days after vaccination

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
9
Status: Approved,Date: 26 November 2021
Objectives 
Endpoints
 
To assess the safety and reactogenicity of 
vaccination with different lots representing 
critical quality attributes around release, 
around the intermediate shelf-life, and near 
the presumed end of shelf-life.
 
Solicited local (injection site) and systemic
adverse events (AEs) for 7 days after
vaccination
 
Unsolicited AEs for 28 days after vaccination
 
Serious adverse events (SAEs) and adverse
events of special interest (AESIs) until
6 months after vaccination
Exploratory
 
To assess the vaccine-induced immune 
responses at 6 months post-vaccination  
 
pre-F ELISA antibody titers at 6 months after
vaccination
 
Neutralizing antibody titers against RSV A2
strain at 6 months after vaccination
HYPOTHESES
To demonstrate the primary objectives, the following hypotheses will be tested sequentially:
Null Hypothesis 1:
Ad26/protein preF RSV vaccine lots representing the critical quality attributes around the intermediate
shelf-life induces inferior geometric mean titers (GMTs) of the pre-F ELISA titers on Day 15, compared to
Ad26/protein preF RSV vaccine lots representing the critical quality attributes near release.
Alternative Hypothesis 1:
Ad26/protein preF RSV vaccine lots representing the critical quality attributes around the intermediate
shelf-life induces non-inferior GMTs of the pre-F ELISA titers on Day 15, compared to Ad26/protein preF
RSV vaccine lots representing the critical quality attributes near release.
Non-inferiority will be shown if the lower limit of the 2-sided 95% confidence interval (CI) around the
estimated geometric mean titer ratio (GMR) of the intermediate shelf-life lots versus the release lots lies
entirely above 0.67.
If non-inferiority is shown for the intermediate shelf-life lots then the following hypotheses will be tested:
Null Hypothesis 2:
Ad26/protein preF RSV vaccine lots representing the critical quality attributes near the presumed end of
shelf-life induces inferior GMTs of the pre-F ELISA titers on Day 15, compared to Ad26/protein preF RSV
vaccine lots representing the critical quality attributes near release.
Alternative Hypothesis 2:
Ad26/protein preF RSV vaccine lots representing the critical quality attributes near the presumed end of
shelf-life induces non-inferior GMTs of the pre-F ELISA titers on Day 15, compared to Ad26/protein preF
RSV vaccine lots representing the critical quality attributes near release.
Non-inferiority will be shown if the lower limit of the 2-sided 95% CI around the estimated GMR (end of
shelf-life lots versus release lots) lies entirely above 0.67.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
10
Status: Approved,Date: 26 November 2021
OVERALL DESIGN
This is a randomized, double-blind, multicenter, interventional Phase 3 study in adult participants aged
≥60 to ≤75 years. A target of 750 participants will be randomized in parallel in a 1:1:1 ratio to 1 of 3 groups
(see Table 1). Study vaccine will be given by the IM route.
Table 1: 
Study Design
Group  
N 
Vaccination on Day 1
1 
250 
Ad26.RSV.preF 1.0×1011 vp + RSV preF protein 150 μg
(representing critical quality attributes around release)
2 
250 
Ad26.RSV.preF 2.5×1010 vp + RSV preF protein 150 μg
(representing critical quality attributes around the intermediate shelf-life)
3 
250 
Ad26.RSV.preF 1.0×1010 vp + RSV preF protein 150 μg
(representing critical quality attributes near the end of shelf-life)
N = number of participants; vp = viral particles
After vaccination, participants will remain under observation at the study site for at least 15 minutes for
presence of any acute reactions and solicited events. Any unsolicited AEs, solicited local (injection site) or
systemic AEs,and vital signs (systolic and diastolic blood pressure [sitting], heart rate, respiratory rate,and
body temperature) will be documented by study-site personnel following this observation period. In
addition, participants will record solicited signs and symptoms in a participant diary  beginning in the
evening of the day ofvaccination and on a daily basis for 7 days post-vaccination.
Blood will be collected from all participants pre-vaccination and at 14 days and 6 months post-vaccination
to assess humoral immune responses.
Safety issues that might arise from this study may be escalated to an independent Data Monitoring
Committee (DMC),as needed.
The end of the study is defined as the last participant’s last visit.
NUMBER OF PARTICIPANTS
A target of 750 participants will be randomized in parallel in a 1:1:1 ratio to 1 of 3 groups.
VACCINATION GROUPS AND DURATION
The study comprises a screening period (Day -28 to Day 1), vaccination for each participant on Day 1, and
a 6-month safety and immunogenicity follow-up period.
Study Vaccine Administration
The investigational medicinal products (IMPs) to be administered to participants in this study are
Ad26.RSV.preF and RSV preF protein.
The Ad26/protein preF RSV vaccine to be used in this study is composed of Ad26.RSV.preF and RSV preF
protein,to be administered as a single injection (1.0 mL) in the deltoid muscle:
 Ad26.RSV.preF (JNJ-64400141) will be used at a dose level of1.0×1011 viral particles (vp)in Group 1,
2.5×1010 vp in Group 2, and 1.0×1010 vp in Group 3.
 RSV preF protein (JNJ-64213175) will be used at a dose level of 150 μg in all groups (Groups 1 to 3).
Three different lots will be used (a release lot; an aged lot representing the presumed end of shelf-life;
and an aged lot representing the intermediate shelf-life).

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
11
Status: Approved,Date: 26 November 2021
IMMUNOGENICITY EVALUATIONS
Venous blood samples of approximately 10 mL will be collected for the determination of humoral immune
responses. Humoral immunogenicity evaluations are summarized in the table below.
Assay 
Purpose
Primaryand exploratory endpoints
F-protein antibodies 
(RSV-A pre-F ELISA)
Analysis of antibodies binding to RSV-A F-protein in pre-fusion form
Secondary and exploratoryendpoints
RSV A neutralization assay (VNA 
A2)
Analysis of neutralizing antibodies against the RSV A2 strain
ELISA = enzyme-linked immunosorbent assay; VNA = virus neutralization assay
SAFETY EVALUATIONS
Safety assessments will include the monitoring of AEs and vital signs.
AEs and special reporting situations, whether serious or non-serious, that are related to study procedures or
that are related to non-investigational sponsor products will be reported from the time a signed and dated
informed consent form (ICF) is obtained until the end of the study/early withdrawal. Solicited AEs,
collected through  a participant diary will be recorded from the time of vaccination until 7 days post-
vaccination. All other unsolicited AEs and special reporting situations, whether serious or non-serious, will
be reported from the time of vaccination until 28 days post-vaccination. All SAEs,AESIs, and AEs leading
to discontinuation from the study (regardless of the causal relationship) are to be reported from the moment
of vaccination until completion of the participant’s last study-related procedure, which may include contact
for safety follow-up. All AEs will be followed until resolution or until clinically stable.
STATISTICAL METHODS
Sample Size Determination
Sample size calculations are performed under the following assumptions:
 
a 10% decrease in GMT of the groups with aged lots (Group 2 and Group 3) versus the group with the
non-aged lot (Group 1)(ie, assuming a true GMR of Day 15 pre-F ELISA titers equal to 0.9)
 
a standard deviation of 1.3 at the log2 scale for pre-F ELISA on Day 15a
 
a non-inferiority margin of 0.67 (2/3)
 
a 2-sided αof 5%
 
hierarchical testing (ie, first Group 2 versus Group 1; if non-inferiority is demonstrated, then Group 3
versus Group 1)
A total of 236 evaluable participants per group are needed to have 95% power to demonstrate non-inferiority
for each comparison separately. With this sample size, the overall power to demonstrate non-inferiority of
Group 3 versus Group 1 as the second comparison in the hierarchy is at least 90%.
To account for exclusions from the Per-protocolImmunogenicity(PPI)Set (see below for the definitions of
analysis sets), dropouts,and missing samples, approximately 250 participants per group should be enrolled.
a Based on the standard deviation of pre-F ELISA at 14 days after vaccine administration observed in Group 14 of
study VAC18193RSV1004.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
12
Status: Approved,Date: 26 November 2021
Populations for Analysis Sets
The Full Analysis (FA) Set will include all participants who received study vaccine, regardless of the
occurrence of protocol deviations. All safety and participant information analyses will be based on the FA
Set.
The PPI Set will include all randomized participants who received study vaccine and for whom
immunogenicity data are available. Samples taken after a participant experiences a major protocol deviation
expected to impact the immunogenicity outcomes will be excluded from the PPI analysis.
The list of major protocol deviations that would lead to elimination from the immunogenicity analysis will
be specified in the statistical analysis plan (SAP) or major protocol violation criteria document, which will
be finalized before database lock and unblinding.
The primary analysis set for analyses related to RSV immunogenicity is the PPI Set. As a sensitivity
analysis, key tables may also be based on the FA Set.
Immunogenicity Analyses
The primary immunogenicity objective will be assessed by calculating the 2-sided 95% CIs for the
difference in log-transformed Day 15 pre-F ELISA titers for each of the comparisons (ie, Group 2 versus
Group 1, and Group 3 versus Group 1).
The CIs will be calculated via an analysis of variance (ANOVA) including all groups (ie, Groups 1 to 3)
with the log-transformed Day 15 pre-F ELISA titers as dependent variable and group as independent
variable. The CIs around the difference will be back-transformed (by exponentiation) to CIs around a GMR
(GMTGroup x/GMTGroup 1 where x is 2 or 3) and compared to the non-inferiority margin of 0.67 (2/3).
Non-inferiority of Group 2 versus Group 1 is demonstrated if the 2-sided 95% CI for the GMR (GMTGroup 2/
GMTGroup 1) of the Day 15 pre-F ELISA titers lies entirely above 0.67. If non-inferiority of Group 2 versus
Group 1 is not demonstrated, the study fails. If non-inferiority of Group 2 versus Group 1 is demonstrated,
then non-inferiority of Group 3 versus Group 1 can be tested: similarly, non-inferiority of Group 3 versus
Group 1 is demonstrated if the 2-sided 95% CI for the GMR (GMTGroup 3/GMTGroup 1) of the Day 15 pre-F
ELISA titers lies entirely above 0.67.
As a sensitivity analysis to assess the impact of baseline titers, the primary endpoint will also be evaluated
adjusting for the respective baseline titers. For immunogenicity, baseline is considered as the last
assessment pre-vaccination. In a second sensitivity analysis, different variances between the study groups
will be allowed. Therefore, the CIs will be calculated via Welch’s ANOVA.
No formal statistical testing of the secondary and exploratory immunogenicity endpoints is planned.
Immunogenicity data will be summarized descriptively by group. Descriptive statistics of the actual values
(eg, geometric mean and 95% CI) will be calculated for continuous parameters at all timepoints. Geometric
mean fold rises from baseline and corresponding 95% CIs will also be calculated. Baseline is considered
the last available assessment prior to vaccination. Graphical representations will be prepared, as applicable.
GMRs (GMTGroup 2/GMTGroup 1 andGMTGroup 3/GMTGroup 1) will also be calculated for VNA A2 in a similar
manner as for pre-F ELISA. Frequency tabulations will be calculated for discrete (qualitative) parameters,
as applicable.
Safety Analyses
No formal statistical testing of safety data is planned. All safety data will be analyzed descriptively by
group. All safety analyses will be based on the FA Set.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
13
Status: Approved,Date: 26 November 2021
1.2. 
Schema
Figure 1: 
Schematic Overview of the Study
* By telephone
Safety –7 days after study vaccination*
2
3
4
5
6
VISIT
Immunogenicity and Safety –14 days after study vaccination
Safety –28 days after study vaccination*
Immunogenicity and Safety –6 months after study vaccination
Vaccination: Day 1
1 
Screening: Day -28 to 1

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
15
Status: Approved,Date: 26 November 2021
pre-vaccination; pre- and post-vaccination; solicited local (injection site)and solicited systemic AEs will be collected via participant diaries from vaccination
until 7 days post-vaccination; if within 7 days of vaccination; if the early exit visit is within 28 days of vaccination.
Note: At any clinic visit, an abbreviated, symptom-directed physical examination may be performed if deemed necessary by the investigator based on any clinically
relevant issues, clinically relevant symptoms, and medical history.
Footnotes:
a. 
Screening will be performed within 28 days prior to the study vaccination or on the day of vaccination. If screening is performed on the day of vaccination
(recommended), Visit 1 and Visit 2 will coincide on Day 1. In that case, assessments should only be done once. Screening must be completed and all eligibility
criteria must be fulfilled prior to randomization and vaccination.
b. 
Safety visits and early exit visit will be by telephone.
c. 
An early exit visit will be conducted as soon as possible for those participants who are unable to continue participation in the study and withdraw from the study
before Day 183, but who do not withdraw consent. Participants who wish to withdraw consent from participation in the study will be offered an early exit visit
(prior to formal withdrawal of consent).
d. 
Signing of the ICF should be done before any study-related activity.
e. 
Medical history of all participants will be recorded in the eCRF, including whether each condition places the participant at increased risk for severe RSV disease.
The conditions placing a participant at increased risk of severe RSV disease include: congestive heart failure, coronary artery disease (such as angina pectoris,
ischemic cardiomyopathy, history of myocardial infarct, or history of coronary artery bypass graft or coronary artery stent),and chronic lung disease (such as
asthma and chronic obstructive pulmonary disease.
As part of the medical history, the investigator must also collect and document risk factors for blood clotting events and thrombocytopenia at screening. As done
for any other medical history events, the information must be entered on the relevant eCRF pages such as Medical History page or Concomitant Medication page.
f. 
Prestudy therapies administered up to 30 days pre-vaccination must be recorded on Day 1.
g. 
Sitting systolic and diastolic blood pressure,heart rate,and respiratory rate after at least 5 minutes rest on Day 1. At non-vaccination visits, vital signs will be measured
if deemed necessary by the investigator.
h. 
The investigator must check for clinically significant acute illness at the time of vaccination or body temperature ≥38.0°C (≥100.4°F) within 24 hours prior to the
planned time of vaccination. In such cases, the participant may be vaccinated up to, and no later than 10 days after the scheduled vaccination, or be withdrawn at the
discretion of the investigator.
i. 
After vaccination, participants will remain under observation at the study site for at least 15 minutes for presence of any acute reactions and solicited events. Any
unsolicited AEs, solicited local (injection site) or systemic AEs, and vital signs (systolic and diastolic blood pressure [sitting], heart rate, respiratory rate, and body
temperature) will be documented by study-site personnel following this observation period.
j. 
AESIs, including potential AESIs, are to be reported to the sponsor from the moment of vaccination until 6 months after the vaccination. See Section 8.3.6.
k. 
Concomitant therapies will be collected from the time of study vaccination through 28 days post-vaccination when associated with an AE, and from ICF signature
until 6 months post-vaccination when associated with an SAE or AESI.
l. 
Any history of SARS-CoV-2 vaccination (name/manufacturer of the vaccine and date of administration, whenever possible) prior to and during the study will be
collected in the eCRF.
m. Rulers and thermometers will be distributed at Visit 2.
n. 
Participants will be contacted by telephone 2 to 4 days post-vaccination to remind them to fill in the participant diaries and to check that they are entering information
correctly.
o. 
Aliquots of serum samples collected for immunogenicity tests can be reconverted for participant’s safety purposes upon sponsor request. Please refer to Table 4 for
a non-exhaustive list of tests that may be requested to be performed on these samples in case of potential AESI reporting.
p. 
Includes the assessment of the severity of solicited AEs during the Visit 3 phone call.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
16
Status: Approved,Date: 26 November 2021
q. 
Includes the assessment of the severity of unsolicited AEs and the occurrence of special reporting situations during all visits up to 28 days post-vaccination, including
the Visit 3 and Visit 5 phone calls.
AE = adverse event; AESI = adverse event of special interest; d = days; ICF = informed consent form; mo = months; SAE = serious adverse event; SARS-CoV-2 = Severe
Acute Respiratory Syndrome Coronavirus-2; vac = vaccination

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
17
Status: Approved,Date: 26 November 2021
2. 
INTRODUCTION
The respiratory syncytial virus (RSV) vaccine that will be evaluated in this study, the Ad26/protein
preF RSV vaccine (VAC18193), is a combination of 2 vaccine components,administered as single
intramuscular (IM) injection:
 Ad26.RSV.preF (JNJ-64400141), a replication-incompetent adenovirus serotype 26 (Ad26)
containing a DNA transgene that encodes the prefusion conformation-stabilized F protein
(pre-F) derived from the RSV A2 strain.
 RSV preF protein (JNJ-64213175), a recombinant pre-F protein derived from the RSV A2
strain.
For the most comprehensive nonclinical and clinical information regarding the Ad26/protein preF
RSV vaccine, refer to the latest version of the Investigator’s Brochure (IB) for Ad26/protein preF
RSV vaccine (IB Ad26/protein preF RSV vaccine 2021).
The term “study vaccine” used throughout the protocol refers to the Ad26/protein preF RSV
vaccine as defined in Section 6.1.
The term “sponsor” used throughout this document refers to the entities listed in the Contact
Information page(s), which will be provided as a separate document.
2.1. 
Study Rationale
The aim of this study is to demonstrate the non-inferiority in terms of humoral immune responses
of Ad26/protein preF RSV vaccine lots representing key stability indicating critical quality
attributes (eg, potency of Ad26.RSV.preF, purity of RSV preF protein) halfway (“intermediate
shelf-life”) and at the end of the intended shelf-life (“end of shelf-life”) in comparison to a non-
aged Ad26/protein preF RSV vaccine lot. Demonstrating non-inferior humoral immune responses
of material at “intermediate shelf-life” and at “end of shelf-life” to near release material will allow
to infer efficacy throughout the vaccine shelf-life.
2.2. 
Background
RSV is an important cause of serious respiratory infections in adults aged 60 years and older,
immunocompromised individuals, and those with underlying chronic cardiopulmonary conditions
(Falsey 2005). Exact numbers on the burden of RSV disease in adults aged 60 years and older are
limited. In long-term care facilities, RSV is estimated to infect 5% to 10% of the residents per year
with significant rates of pneumonia (10%-20%) and death (2%-5%) as a consequence (Falsey
2000). In the United States (US), approximately 177,000 hospital admissions and approximately
10,000 to 14,000 deaths per year are due to severe RSV infections in adults aged 65 years and
older (Falsey 2005). These data support the importance of developing a safe and effective vaccine
for certain adult populations, such as older adults. Currently, no vaccines or specific treatments are
available for RSV.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
18
Status: Approved,Date: 26 November 2021
Several studies have indicated that high levels of serum neutralizing antibodies are associated with
a reduced risk of severe RSV infection in older adults (Falsey 1998; Walsh 2004). There is some
indication that decreased protection against RSV in older adults could be attributed to an age-
related decline in RSV-specific T-cell function (de Bree 2005; Looney 2002). The Ad26.RSV.preF
vaccine component evaluated in this study is based on the AdVac® platform, which has been
shown to promote strong humoral and cellular responses (Barouch 2013; Barouch 2018; Data on
file; Milligan 2016).
Nonclinical Studies
Forthemostcomprehensivenonclinicalinformation regarding the Ad26/protein preF RSV vaccine,
refer to the latest version of the IB for Ad26/protein preF RSV vaccine (IB Ad26/protein preF
RSV vaccine 2021).
Clinical Studies
For the most comprehensive clinical information regarding the Ad26/protein preF RSV vaccine,
refer to the latest version of the IB for Ad26/protein preF RSV vaccine (IB Ad26/protein preF
RSV vaccine 2021).
Clinical Safety Experience with Ad26-based Vaccines
The Janssen Adenoviral Vaccine (AdVac) Safety Database Report (version 6.0; AdVac Safety
Database 2021) contains pooled safety data of the following Ad26-based vaccine candidates:
Ad26.ZEBOV (Ebola virus), Ad26.ENVA.01, Ad26.Mos.HIV, and Ad26.Mos4.HIV (HIV),
Ad26.CS.01 (malaria), Ad26.RSV.FA2 and Ad26.RSV.preF (RSV), Ad26.Filo (filovirus),
Ad26.ZIKV.001 (Zika virus), and Ad26.HPV16 and Ad26.HPV18 (HPV). Data from all studies
for which the database had been locked for either the interim, primary, or final analysis for which
the sponsor has been fully unblinded are included in the AdVac Safety Database Report, ie,
32 completed and ongoing unblinded clinical studies (cutoff date of 31 December 2020). In total,
8,826 participants were vaccinated with an Ad26-based vaccine. Of these 8,826 participants,
8,152 participants (in all 32 studies) were adults, and 674 participants (in 3 studies) were children.
The report also provides a high-level overview of all clinical study SAEs and vaccine exposure
during pregnancy cases reported in the Janssen Global Safety Database that also includes all
ongoing (open-label and blinded) studies, non-Janssen sponsored studies, and mass vaccination
campaigns which are not integrated in the AdVac Safety Database Report. This data set includes
also SAEs and pregnancy cases of Ad26.COV2.S (Janssen COVID-19 vaccine) vaccine clinical
studies. About 200,000 participants were dosed with an Ad26-based vaccine at the cutoff date of
31 December 2020.
No significant safety issues have been identified from the data available in the current adenoviral
vaccine safety database. Overall, the Ad26-based vaccines were well tolerated, without significant
safety issues identified.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
19
Status: Approved,Date: 26 November 2021
Thrombosis With Thrombocytopenia Syndrome
Thrombosis in combination with thrombocytopenia (thrombosis with thrombocytopenia syndrome
[TTS]), in some cases accompanied by internal bleeding, has been observed very rarely following
vaccination with the Janssen COVID-19 (Ad26.COV2.S) vaccine. Reports include severe cases of
venous thrombosis at unusual sites such as cerebral venous sinus thrombosis (CVST), splanchnic
vein thrombosis and arterial thrombosis, in combination with thrombocytopenia. The associated
symptoms began approximately 1 to 2 weeks after vaccination, mostly in women under 60 years
of age. Thrombosis in combination with thrombocytopenia can be fatal. The exact
pathophysiology of TTS is unclear. This event has not been observed to date with any other
Janssen Ad26-based vaccines. Participants should be instructed to seek immediate medical
attention if they develop symptoms such as shortness of breath, chest pain, leg swelling, persistent
abdominal pain, severe or persistent headaches, blurred vision, skin bruising or petechiae beyond
the site of vaccination.
2.3. 
Benefit-Risk Assessment
More detailed information about the known and expected benefits and risks of the Ad26/protein
preF RSV vaccine may be found in the IB for Ad26/protein preF RSV vaccine (IB Ad26/protein
preF RSV vaccine 2021).
2.3.1. 
Risks Related to Study Participation
The following potential risks for the Ad26/protein preF RSV vaccine will be monitored during the
study:
Risks Related to Ad26/protein preF RSV Vaccine
The Ad26/protein preF RSV vaccine is currently being studied in 4 ongoing studies in more than
6,500 participants aged 60 years and older, including participants with comorbidities, to assess
safety and immunogenicity and to investigate whether the vaccine prevents RSV disease. In these
studies, the most commonly reported solicited local adverse events (AEs) were injection site
pain/tenderness and swelling (mild to moderate). The most frequently reported solicited systemic
AEs were fatigue, muscle pain, headache, chills, joint pain, and nausea, which were mild to
moderate in severity. These solicited AEs were short-lived and resolved within a few days. Overall,
available results from these studies show the vaccine to be well-tolerated with no safety concerns.
General Risks Related to Vaccination
In general, IM injection may cause local itching, warmth, pain, tenderness, erythema/redness,
induration, swelling, arm discomfort, or bruising of the skin. Participants may exhibit general signs
and symptoms associated with IM injection of a vaccine, including fever, chills, rash, myalgia,
nausea/vomiting, headache, dizziness, arthralgia, general itching, and fatigue. These side effects
will be monitored,but are generally short-term and do not require treatment.
Syncope can occur in association with administration of injectable vaccines. Syncope can be
accompanied by falls. Procedures should be in place to avoid falling injury. If syncope develops,

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
20
Status: Approved,Date: 26 November 2021
participants should be observed until the symptoms resolve. Fear of injection might lead to fainting
and fast breathing.
Participants may have an allergic reaction to the vaccination. An allergic reaction may cause a
rash, urticaria, or even anaphylaxis. Severe reactions are rare. Participants with a known or
suspected allergy, or with a history of anaphylaxis or other serious adverse reactions to vaccines
or their excipients (including specifically the excipients of the study vaccine), will be excluded
from the study.
After vaccination, participants will remain at the study site for at least 15 minutes and will be
closely observed by study staff. Necessary emergency equipment and medications must be
available in the clinic to treat severe allergic reactions.
Pregnancy and Birth Control
The effect of the Ad26/protein preF RSV vaccine on a fetus or nursing baby is unknown.
Participants may therefore only participate if they are postmenopausal (defined as no menses for
12 months without an alternative medical cause) and not intending to conceive by any methods.
Participants who are surgically sterile are also eligible for the study. Follow-up information
regarding the outcome of the pregnancy will be required.
Because the effect on sperm is unknown, participants must inform the study-site personnel if their
partner becomes pregnant during the study. Follow-up information regarding the outcome of the
pregnancy will be requested upon the consent provided by the partner.
Participants with Immunosuppression/Reduced Immune Response
Participants with abnormal function of the immune system will be excluded from the study.
Limited evidence indicates that inactivated vaccines (or nonreplicating viral vaccines) generally
have the same safety profile in immunocompromised patients as in immunocompetent individuals.
However, the magnitude, breadth, and persistence of the immune response to vaccination may be
reduced or absent in immunocompromised persons.
Risks from Blood Draws
Blood draws may cause pain, tenderness, bruising, bleeding, dizziness, vasovagal response,
syncope, and rarely, infection at the site where the blood is taken. Participants with
contraindications to IM injections and blood draws (eg, bleeding disorders) will be excluded.
Concomitant Vaccination
Concomitant vaccination might have an influence on both the safety profile and immunogenicity
of the Ad26/protein preF RSV vaccine. Likewise, the Ad26/protein preF RSV vaccine might have
an influence on both the safety profile and immunogenicity of any concomitant vaccination. As a
result, licensed live attenuated vaccines should be given at least 28 days before or after vaccination.
Other licensed (not live) vaccines (eg, influenza, tetanus, hepatitis A, hepatitis B, rabies) should
be given at least 14 days before or after vaccination to avoid potential confusion of adverse

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
21
Status: Approved,Date: 26 November 2021
reactions and potential immune interference. If a vaccine is indicated in a postexposure setting (eg,
rabies or tetanus), it must take priority over the study vaccine.
For Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) vaccines licensed or
available under Emergency Use Authorization: live attenuated vaccines should be given at least
28 days before or after vaccination; non-live vaccines should be given at least 14 days before or
after vaccination. A viral-vectored SARS-CoV-2 vaccine is not to be given at any time prior to
randomization or during the study period until 28 days after study vaccination.
Unknown Risks
There may be other risks that are not known. If any significant new risks are identified, the
investigators and participants will be informed.
2.3.2. 
Benefits of Study Participation
Participants may benefit from clinical testing.
The clinical benefits of the Ad26/protein preF RSV vaccine have yet to be confirmed.
The Ad26/protein preF RSV vaccine is under development for prophylaxis of RSV disease and
vaccine efficacy is being evaluated in ongoing studies. Results from the primary analysis of study
VAC18193RSV2001 with approximately 5,800 participants showed the potential for the vaccine
to prevent lower respiratory tract disease caused by RSV in participants 65 years and older.
2.3.3. 
Benefit-Risk Assessment of Study Participation
Based on the available data and proposed safety measures, the overall benefit-risk assessment for
this clinical study is considered acceptable for the following reasons:
 The dose levels of Ad26.RSV.preF and RSV preF protein used in the current study were
determined from the primary analysis of Cohort 2 in study VAC18193RSV1004 and are
currently under further evaluation in studies VAC18193RSV1004 and VAC18193RSV2001.
Lower dose levels of Ad26.RSV.preF were evaluated in studies VAC18193RSV1004 and
VAC18193RSV2005. The available safety data from all studies show the vaccine to be well-
tolerated with no safety concerns. For details on the justification for dose levels selected for
this study, see Section 4.3. In the primary analysis of study VAC18193RSV2001, vaccine
efficacy was demonstrated for these dose levels in adults aged 65 years and above, for the
prevention of LRTD caused by RSV.
 Only participants who meet all inclusion criteria and none of the exclusion criteria (specified in
Section 5) will be allowed to participate in this study. The selection criteria include adequate
provisions to minimize the risk and protect the well-being of participants in the study.
 Safety will be closely monitored throughout the study:
 In general, safety evaluations will be performed at scheduled visits during the study, as
indicated in the Schedule of Activities.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
22
Status: Approved,Date: 26 November 2021
 After vaccination, participants will remain at the study site for at least 15 minutes and will
be closely observed by study staff. Necessary emergency equipment and medications must
be available in the clinic to treat severe allergic reactions. Participants will use a participant
diary to document solicited signs and symptoms. Details are provided in Section 8.2.
 The investigator or the designee will document unsolicited AEs, serious adverse events
(SAEs), and adverse events of special interest (AESIs)as indicated in Sections 8.2 and 8.3
and Appendix 2.
 Any clinically significant abnormalities will be followed by the investigator until resolution
or until clinically stable.
 After vaccination, participants will enter a 6-month safety follow-up period for collection
of SAEs and AESIs.
 All AEs,SAEs, and AESIs will be followed by the investigator until clinical resolution or
until a clinically stable condition is reached, or until the participant has been deemed lost
to follow-up after demonstration of due diligence of follow-up efforts. An early exit visit
will be conducted for those participants who are unable to continue participation in the
study and withdraw from the study before Day 183, but who do not withdraw consent.
Participants who wish to withdraw consent from participation in the study will be offered
an early exit visit (prior to formal withdrawal of consent) (Section 7.2).
 Several safety measures are included in this protocol to minimize the potential risk to
participants, including the following:
 Safety issues that might arise from this study may be escalated to an independent Data
Monitoring Committee (DMC),as needed.
 Study vaccinations will be discontinued in participants for the reasons described in
Section 7.
 Temporary contraindications to study vaccination are described in Section 5.5.
3. 
OBJECTIVES AND ENDPOINTS
Objectives 
Endpoints
Primary
 
To demonstrate non-inferiority in terms of
humoral immune responses induced by
Ad26.RSV.preF-based study vaccine lots
representing the critical quality attributes
around the intermediate shelf-life to
Ad26.RSV.preF-based study vaccine lots
representing the critical quality attributes
near release.
 
pre-F enzyme-linked immunosorbent assay
(ELISA) antibody titers at 14 days after
vaccination.
 
If non-inferiority is demonstrated for the
Ad26.RSV.preF-based study vaccine lots
representing the critical quality attributes
around the intermediate shelf-life:
 
pre-F ELISA antibody titers at 14 days
after vaccination.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
23
Status: Approved,Date: 26 November 2021
Objectives 
Endpoints
To demonstrate non-inferiority in terms of
humoral immune responses induced by
Ad26.RSV.preF-based study vaccine lots
representing the critical quality attributes
near the presumed end of shelf-life to
Ad26.RSV.preF-based study vaccine lots
representing the critical quality attributes
near release.
Secondary
 
To assess neutralizing antibody responses 
following vaccination  
 
Neutralizing antibody titers against RSV A2
strain at 14 days after vaccination
 
To assess the safety and reactogenicity of 
vaccination with different lots representing 
critical quality attributes around release, 
around the intermediate shelf-life, and near
the presumed end of shelf-life.
 
Solicited local (injection site) and systemic
AEs for 7 days after vaccination.
 
Unsolicited AEs for 28 days after
vaccination.
 
SAEs and AESIs until 6 months after
vaccination.
Exploratory
 
To assess the vaccine-induced immune 
responses at 6 months post-vaccination 
 
pre-F ELISA antibody titers at 6 months after
vaccination
 
Neutralizing antibody titers against RSV A2
strain at 6 months after vaccination
Refer to Section 8 for evaluations related to endpoints.
HYPOTHESES
To demonstrate the primary objectives, the following hypotheses will be tested sequentially:
Null Hypothesis 1:
Ad26/protein preF RSV vaccine lots representing the critical quality attributes around the
intermediate shelf-life induces inferior geometric mean titers (GMTs) of the pre-F ELISA titers on
Day 15, compared to Ad26/protein preF RSV vaccine lots representing the critical quality
attributes near release.
Alternative Hypothesis 1:
Ad26/protein preF RSV vaccine lots representing the critical quality attributes around the
intermediate shelf-life induces non-inferior GMTs of the pre-F ELISA titers on Day 15, compared
to Ad26/protein preF RSV vaccine lots representing the critical quality attributes near release.
Non-inferiority will be shown if the lower limit of the 2-sided 95% confidence interval (CI) around
the estimated geometric mean titer ratio (GMR) of the intermediate shelf-life lots versus the release
lots lies entirely above 0.67.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
24
Status: Approved,Date: 26 November 2021
If non-inferiority is shown for the intermediate shelf-life lots then the following hypotheses will
be tested:
Null Hypothesis 2:
Ad26/protein preF RSV vaccine lots representing the critical quality attributes near the presumed
end of shelf-life induces inferior GMTs of the pre-F ELISA titers on Day 15, compared to
Ad26/protein preF RSV vaccine lots representing the critical quality attributes near release.
Alternative Hypothesis 2:
Ad26/protein preF RSV vaccine lots representing the critical quality attributes near the presumed
end of shelf-life induces non-inferior GMTs of the pre-F ELISA titers on Day 15, compared to
Ad26/protein preF RSV vaccine lots representing the critical quality attributes near release.
Non-inferiority will be shown if the lower limit of the 2-sided 95% CI around the estimated GMR
(end of shelf-life lots versus release lots) lies entirely above 0.67.
4. 
STUDY DESIGN
4.1. 
Overall Design
This is a randomized,double-blind, multicenter, interventional Phase 3 study in adult participants
aged ≥60 to ≤75 years. A target of 750 participants will be randomized in parallel in a 1:1:1 ratio
to 1 of 3 groups (see Table 2).
All participants will receive Ad26/protein preF RSV vaccine on Day 1 by the IM route.
Table 2: 
Study Design
Group  
N 
Vaccination on Day 1
1 
250 
Ad26.RSV.preF 1.0×1011 vp + RSV preF protein 150 μg
(representing critical quality attributes around release)
2 
250 
Ad26.RSV.preF 2.5×1010 vp + RSV preF protein 150 μg
(representing critical quality attributes around the intermediate shelf-life)
3 
250 
Ad26.RSV.preF 1.0×1010 vp + RSV preF protein 150 μg
(representing critical quality attributes near the end of shelf-life)
N = number of participants; vp = viral particles
After vaccination, participants will remain under observation at the study site for at least
15 minutes for presence of any acute reactions and solicited events. Any unsolicited AEs, solicited
local (injection site)orsystemic AEs,and vital signs (systolic and diastolic blood pressure [sitting],
heart rate, respiratory rate, and body temperature) will be documented by study-site personnel
followingthisobservationperiod.In addition,participants will record solicited signs and symptoms
in a participant diary beginning in the evening of the day of vaccination and on a daily basis for
7 days post-vaccination (Section 8).
The reporting periods of AEs,SAEs,and AESIs are detailed in Section 8.3. The reporting periods
for concomitant therapy are outlined in Section 6.8.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
25
Status: Approved,Date: 26 November 2021
Blood will be collected from all participants pre-vaccination and at 14 days and 6 months post-
vaccination to assess humoral immune responses.
Safety issues that might arise from this study may be escalated to an independent DMC,as needed.
The study comprises a screening period (Day -28 to Day 1), vaccination for each participant on
Day 1, and a 6-month safety and immunogenicity follow-up period. The end of the study is defined
as the last participant’s last visit.
Over the entire study, the total blood volume to be collected from each participant will be
approximately 30 mL.
Unscheduled study visits may be performed based on investigator’s clinical judgment and may
include further evaluations, as needed.
A diagram of the study design is provided in Section 1.2 (Figure 1). Further details are provided
in the Schedule of Activities.
4.2. 
Scientific Rationale for Study Design
For the rationale for performing this study, refer to Section 2.1.
Blinding
Randomization will be used to minimize bias in the assignment of participants to vaccination
groups, to increase the likelihood that known and unknown participant attributes (eg,demographic
and baseline characteristics) are evenly balanced across vaccination groups, and to enhance the
validity of statistical comparisons across vaccination groups.
Blinded vaccine will be used to reduce potential bias during data collection and evaluation of
clinical endpoints.
Vaccination Groups
The groups will differ in the dose level (Ad26.RSV.preF) and lots (RSV preF protein) of the study
vaccine (see Table 2). The Ad26/protein RSV preF lots in the different groups were set to represent
vaccine critical quality attributes near release, around the intermediate shelf-life, and near the
presumed end of shelf-life, respectively.
Vaccine Component Selection
The rationale behind the selection of the Ad26/protein preF RSV vaccine is described in
Section 2.2 and in the IB for Ad26/protein preF RSV vaccine (IB Ad26/protein preF RSV vaccine
2021).
Dose Level Selection
The rationale behind the dose level selection for the Ad26/protein preF RSV vaccine is described
in Section 4.3.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
26
Status: Approved,Date: 26 November 2021
4.2.1. 
Study-Specific Ethical Design Considerations
Potential participants will be fully informed of the risks and requirements of the study and, during
the study, participants will be given any new information that may affect their decision to continue
participation. They will be told that their consent to participate in the study is voluntary and may be
withdrawn at any time with no reason given and without penalty or loss of benefits to which they
would otherwise be entitled. Only participants who are fully able to understand the risks, benefits,
and potential AEs of the study, and provide their consent voluntarily will be enrolled.
The primary ethical concern is that this study will be performed in adult participants who will receive
no benefit from participation in the study, except for compensation for the time and inconveniences
that may arise from participation in the study.
See Section 2.3 for Benefit-Risk Assessment.
The total blood volume to be collected is considered to be an acceptable amount of blood to be
collected over this time period from the population in this study based upon the standard of the US
Department of Health and Human Services Office for Human Research Protections, and US FDA
guidelines of 550 mL in any 8-week period (OHRP 1998; FDA 1998).
The results of this study may be made available to all participants through a plain language
summary at the conclusion of the study according to local standards/restrictions.
4.3. 
Justification for Dose
The dose level for the Ad26/protein preF RSV vaccine used in the current study was determined
from the primary analysis of Cohort 2 in study VAC18193RSV1004. From this primary analysis,
a significant increase in humoral immune responses including virus neutralizing antibodies (virus
neutralization assay) and pre-F antibody titers were observed in groups combining Ad26.RSV.preF
(5×1010 vp or 1×1011 vp) and RSV preF protein (50 µg or 150 µg) compared to Ad26.RSV.preF
1×1011 vp alone. No relevant differences between combination groups and Ad26.RSV.preF alone
were noted for cellular immune responses. All regimens had acceptable safety and reactogenicity
profiles, which were similar across groups. Additionally, in the primary analysis of study
VAC18193RSV2001, vaccine efficacy was demonstrated for these dose levels. Based on these
data, the dose levels of Ad26.RSV.preF and RSV preF protein selected for the present study are
1×1011 vp and 150 µg, respectively.
The lower Ad26.RSV.preF dose levels in the current study (Group 2 and Group 3) have been
evaluated in study VAC18193RSV2005. These dose levels were selected based on the primary
and interim analyses of the study in combination with preliminary stability data of Ad26.RSV.preF
drug product manufactured and filled using the intended commercial process. The potency
(infectious units) of the dose level that will be assessed in Group 3 is estimated to be below the
remaining drug product potency around the presumed end of shelf-life (>24 months storage at 2°C
to 8°C).

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
27
Status: Approved,Date: 26 November 2021
Three differentially aged RSV preF protein lots will be used in the study. Participants in Group 1
will receive an RSV preF protein lot that has been recently manufactured (non-aged) representing
the drug product specifications after release. Participants in Group 2 will receive a naturally aged
RSV preF protein lot that has been stored 12 to 24 months at 2°C to 8°C representing the drug
product purity around the intermediate shelf-life. Participants in Group 3 will receive a naturally
aged RSV preF protein lot that has been stored >24 months at 2°C to 8°C representing the drug
product purity around the presumed end of shelf-life.
4.4. 
End of Study Definition
End of Study Definition
The end of study is considered as the last visit (on Day 183) for the last participant in the study.
The final data from the study site will be sent to the sponsor (or designee) after completion of the
final participant visit at that study site, in the time frame specified in the Clinical Trial Agreement.
Participant Study Completion Definition
A participant will be considered to have completed the study if the participant has completed
assessments at the Day 183 visit.
5. 
STUDY POPULATION
Screening for eligible participants will be performed within 28 days prior to the study vaccination
or on the day of vaccination.a Refer to Section 5.4 for conditions under which the repeat of any
screening procedures are allowed.
The inclusion and exclusion criteria for enrolling participants in this study are described below. If
there is a question about these criteria, the investigator must consult with the appropriate sponsor
representative and resolve any issues before enrolling a participant in the study. Waivers are not
allowed.
For a discussion of the statistical considerations of participant selection, refer to Section 9.2.
5.1. 
Inclusion Criteria
Each potential participant must satisfy all of the following criteria to be enrolled in the study:
1. 
must sign an informed consent form (ICF) indicating that the participant understands
the purpose, procedures and potential risks and benefits of the study, and is willing to
participate in the study.
a If screening is performed on the day of vaccination (recommended), Visit 1 and Visit 2 will coincide on Day 1. In
that case, assessments should only be done once. Screening must be completed and all eligibility criteria must be
fulfilled prior to randomization and vaccination.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
28
Status: Approved,Date: 26 November 2021
2. 
must be willing and able to adhere to the prohibitions and restrictions specified in this
protocol.
3. 
Criterion modified per Amendment 2
3.1 
aged ≥60 to ≤75 years on the day of signing the ICF and expected to be available
for the duration of the study.
4. 
before randomization, a participant must be:
a. postmenopausal (postmenopausal state is defined as no menses for 12 months
without an alternative medical cause); and
b. not intending to conceive by any methods.
Note: Surgically sterile participants are also eligible for the study.
5. 
in the investigator’s clinical judgment, a participant must be in stable health at the time
of vaccination. Participants may have underlying illnesses such as hypertension,
congestive heart failure, chronic obstructive pulmonary disease, Type 2 diabetes,
hyperlipoproteinemia, or hypothyroidism, as long as their symptoms and signs are
stable at the time of vaccination, and these conditions receive routine follow-up by the
participant’s healthcare provider. Participants will be included on the basis of medical
history and vital signsa performed between ICF signature and vaccination.
6. 
from the time of vaccination through 3 months after vaccination, agrees not to donate
blood.
7. 
must be able to read, understand, and complete questionnaires in the eDiary.
8. 
must be willing to provide verifiable identification, has means to be contacted and to
contact the investigator during the study.
9. 
must be able to work with smartphones/tablets/computers.
5.2. 
Exclusion Criteria
Any potential participant who meets any of the following criteria will be excluded from
participating in the study:
1. 
Criterion modified per Amendment 2
1.1 
history of malignancy within 5 years before screening not in the following
categories:
a. Participants with squamous and basal cell carcinomas of the skin and carcinoma
in situ of the cervix may be enrolled at the discretion of the investigator.
a Participants can be enrolled with Grade 1 or Grade 2 values for vital signs measurements (refer to Appendix 4:
Toxicity Grading Scale).

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
29
Status: Approved,Date: 26 November 2021
b. Participants with a history of malignancy within 5 years before screening, with
minimal risk of recurrence per investigator’s judgement, can be enrolled.
2. 
known or suspected allergy or history of anaphylaxis or other serious adverse reactions
to vaccines or their excipients (including specifically the excipients of the study
vaccine)(refer to IB Ad26/protein preF RSV vaccine 2021).
Note: Participants with egg allergies can be enrolled.
3. 
abnormal function of the immune system resulting from:
a. Clinical conditions (eg, autoimmune disease or immunodeficiency expected to have
an impact on the immune response elicited by the study vaccine. Participants with
autoimmune disease (eg, autoimmune-mediated thyroid disease, autoimmune
inflammatory rheumatic disease such as rheumatoid arthritis, and Type 1 diabetes)
that is stable and inactive without the use of systemic immunomodulators and
glucocorticoids may be enrolled at the discretion of the investigator.
b. Use of systemic corticosteroids within 2 months before administration of study
vaccine until 14 days after study vaccination.
Note: Ocular, topical, or inhaled steroids are allowed.
c. Administration of antineoplastic and immunomodulating agents, eg, cancer
chemotherapeutic agents, or radiotherapy within 6 months before administration of
study vaccine until 14 days after study vaccination.
4. 
per medical history, participant has chronic active hepatitis B or hepatitis C infection.
5. 
per medical history, participant has human immunodeficiency virus (HIV) type 1 or
type 2 infection.
6. 
history of acute polyneuropathy (eg, Guillain-Barré syndrome) or chronic idiopathic
demyelinating polyneuropathy.
7. 
Criterion modified per Amendment 2
7.1 
received hematopoietic stem cell transplant in medical history, treatment with
immunoglobulins expected to impact the vaccine-induced immune response
(including monoclonal antibodies for chronic underlying conditions) in the
2 months, immunoglobulins specific to RSV, human metapneumovirus, or
parainfluenza viruses in the 12 months, apheresis therapies in the 4 months, or
blood products in the 4 months before the planned administration of study
vaccine or has any plans to receive such treatment during the study.
Note: The investigator is encouraged to contact the sponsor to discuss eligibility
of participants on immunoglobulin treatment.
8. 
history of TTS or heparin-induced thrombocytopenia and thrombosis (HITT).

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
30
Status: Approved,Date: 26 November 2021
9. 
received or plans to receive:
a. licensed live attenuated vaccines within 28 days before or after the planned
administration of study vaccine.
b. other licensed (not live) vaccines within 14 days before or after the planned
administration of study vaccine.
10. 
Criterion modified per Amendment 2
10.1 received or plans to receive a SARS-CoV-2 vaccine:
a. live attenuated SARS-CoV-2 vaccine within 28 days before or after planned
administration of study vaccine.
b. non-live SARS-CoV-2 vaccine within 14 days before or after planned
administration of study vaccine.
c. viral-vectored SARS-CoV-2 vaccine within 6 months prior to randomization
or during the study period until 28 days after study vaccination.
11. 
received an RSV vaccine in a previous RSV vaccine study.
12. 
received or plans to receive an Ad26-vectored vaccine at any time prior to
randomization until 28 days after study vaccination (this does not apply to SARS-
CoV-2 vaccines: for exclusion criteria related to SARS-CoV-2 vaccines, please refer to
Exclusion Criterion 10).
13. 
Criterion modified per Amendment 2
13.1 received an investigational drug or used an invasive investigational medical
device within 30 days or received an investigational vaccine within 6 months
before the planned administration of the study vaccine or is currently enrolled or
plans to participate in another investigational study during this study.
Note: Participation in an observational clinical study (ie, without intervention)
or in the observational phase of interventional studies is allowed upon approval
of the sponsor or its delegate.
14. 
has a serious chronic disorder, eg, severe chronic obstructive pulmonary disease or
severe congestive heart failure, end-stage renal disease with or without dialysis,
clinically unstable cardiac disease, Alzheimer’s disease, or has any condition for which,
in the opinion of the investigator, participation would not be in the best interest of the
participant (eg, compromise the well-being) or that could prevent, limit, or confound
the protocol-specified assessments.
15. 
has had major surgery (per the investigator’s judgment) within 4 weeks before
administration of the study vaccine or will not have recovered from surgery per the
investigator’s judgment at time of vaccination.
16. 
contraindication to IM injections and blood draws (eg, bleeding disorders).

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
31
Status: Approved,Date: 26 November 2021
17. 
employee of the investigator or study site, with direct involvement in the proposed study
or other studies under the direction of that investigator or study site, as well as family
members of the employees or the investigator, or an employee of the sponsor.
18. 
has had major psychiatric illness and/or drug or alcohol abuse which in the
investigator’s opinion would compromise the participant’s safety and/or compliance
with the study procedures.
19. 
cannot communicate reliably with the investigator.
20. 
who, in the opinion of the investigator, is unlikely to adhere to the requirements of the
study, or is unlikely to complete the full course of vaccination and observation.
21. 
who has significant scarring, tattoos, abrasions, cuts, or infections over the deltoid
region of both arms that, in the investigator’s opinion, could interfere with evaluation
of injection site local reactions.
NOTE: Investigators should ensure that all study enrollment criteria have been met prior to
vaccination. If a participant’s clinical status changes (including any available laboratory results or
receipt of additional medical records) after screening but before the study vaccine is given such
that the participant no longer meets all eligibility criteria, then the participant should be excluded
from participation in the study. Section  5.4 describes options for rescreening. The required
documentation to support meeting the enrollment criteria is described under Source Documents in
Appendix 3.
5.3. 
Lifestyle Considerations
Potential participants must be willing and able to adhere to the following lifestyle restrictions
during the study to be eligible for participation:
1. 
refer to Section 6.8,Concomitant Therapyfor details regarding prohibited and restricted
therapy during the study.
2. 
agree to follow all requirements that must be met during the study as noted in the
Inclusion and Exclusion Criteria.
5.4. 
Screen Failures
Participant Identification, Enrollment, and Screening Logs
The investigator agrees to complete a participant identification and enrollment log to permit easy
identification of each participant during and after the study. This document will be reviewed by
the sponsor study-site contact for completeness.
The participant identification and enrollment log will be treated as confidential and will be filed
by the investigator in the study file. To ensure participant confidentiality, no copy will be made.
All reports and communications relating to the study will identify participants by participant

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
32
Status: Approved,Date: 26 November 2021
identification and age at initial informed consent. In cases where the participant is not randomized
into the study, the date seen and age at initial informed consent will be used.
Rescreening is allowed only for resolution of an acute condition or meeting a time window (eg,for
a prohibited medication). Only 1 rescreening per participant is permitted. Rescreened participants
will be assigned a new participant number, undergo the informed consent process, and then restart
a new screening phase.
5.5. 
Criteria for Temporarily Delaying Study Vaccine Administration
The following events constitute a temporary contraindication to study vaccination:
 Clinically significant acute illness at the time of vaccination. This does not include minor
illnesses, such as diarrhea or mild upper respiratory tract infection.
 Fever (body temperature ≥38.0°C [≥100.4°F]) within 24 hours prior to the planned time of
vaccination.
If any of these events occur at the scheduled time for vaccination, randomization at a later date
within the screening window (allowed window up to 10 days)is permitted at the discretion of the
investigator and after consultation with the sponsor. If randomization cannot occur within the
screening window, rescreening is required.
If the vaccination visit cannot be rescheduled within the allowed window or the contraindications
to vaccination persist, the sponsor should be contacted for further guidance.
6. 
STUDY VACCINE(S) AND CONCOMITANT THERAPY
6.1. 
Study Vaccine Administration
The investigational medicinal products (IMPs) to be administered to participants in this study are
Ad26.RSV.preF and RSV preF protein.
The Ad26/protein preF RSV vaccine to be used in this study is composed of Ad26.RSV.preF and
RSV preF protein, to be administered as a single injection (1.0 mL) in the deltoid muscle:
 Ad26.RSV.preF (JNJ-64400141) will be used at a dose level of 1.0×1011 viral particles (vp)
in Group 1, 2.5×1010 vp in Group 2, and 1.0×1010 vp in Group 3.
 RSV preF protein (JNJ-64213175) will be used at a dose level of 150 μg in all groups
(Groups 1 to 3). Three different lots will be used (a release lot; an aged lot representing the
presumed end of shelf-life; and an aged lot representing the intermediate shelf-life).
Ad26.RSV.preF and RSV preF protein will be manufactured and provided under the responsibility
of the sponsor. Labels will contain information to meet the applicable regulatory requirements.
Note that RSV preF protein will be labelled as “RSV-F Vaccine”. Refer to the IB for Ad26/protein
preF RSV vaccine for details on the components and a list of the excipients (IB Ad26/protein preF
RSV vaccine 2021).

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
33
Status: Approved,Date: 26 November 2021
Participants will be vaccinated at the study site according to the schedule shown in Table 2. On
Day 1, each participant will receive an IM injection of Ad26/protein preF RSV vaccine.
Study vaccine administration must be captured in the source documents and the electronic case
report form (eCRF).
For a definition of study vaccine overdose, refer to Section 6.7.
6.2. 
Preparation/Handling/Storage/Accountability
Preparation/Handling/Storage
Vials must be stored in a secured location under controlled temperature with no access for
unauthorized personnel. The study refrigerator/freezer must be equipped with a continuous
temperature monitor and alarm and should be equipped with back-up power systems. If the study
vaccine components are exposed to temperatures outside the specified temperature range, all
relevant data will be sent to the sponsor to determine if the affected study vaccine components can
be used or will be replaced. The affected study vaccine components must be quarantined and not
used until further instruction from the sponsor is received.
An unblinded study-site pharmacist, or other qualified individual will prepare the appropriate vials
and syringes, labeled with the participant’s identification number, and provide the syringes for
Ad26/protein preF RSV vaccine in a blinded manner to the blinded study vaccine administrator
who will perform the injection.
Refer to the Investigational Product Preparation Instructions and Study Site Investigational
Product and Procedures Manual for additional guidance on study vaccine preparation, handling,
and storage.
Accountability
The investigator is responsible for ensuring that all study vaccine received at the site is inventoried
and accounted for throughout the study. The study vaccine administered to the participant must be
documented on the vaccine accountability form. All study vaccine will be stored and disposed of
according to the sponsor’s instructions.
Study vaccine must be handled in strict accordance with the protocol and the container label, and
must be stored at the study site in a limited-access area or in a locked cabinet under appropriate
environmental conditions. Unused study vaccine must be available for verification by the
sponsor’s study-site monitor during on-site monitoring visits. The return to the sponsor of unused
study vaccine will be documented on the vaccine return form. When the study site is an authorized
destruction unit and study vaccine supplies are destroyed on site, this must also be documented on
the vaccine return form.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
34
Status: Approved,Date: 26 November 2021
Potentially hazardous materials containing hazardous liquids, such as used ampules, needles,
syringes, and vials, should be disposed of immediately in a safe manner and therefore will not be
retained for vaccine accountability purposes.
Study vaccine should be dispensed under the supervision of the investigator or a qualified member
of the study-site personnel. Study vaccine will be supplied only to participants participating in the
study. Study vaccine may not be relabeled or reassigned for use by other participants. The
investigator agrees neither to dispense the study vaccine from, nor store it at, any site other than
the study sites agreed upon with the sponsor.
Refer to the Investigational Product Preparation Instructions and Study Site Investigational
Product and Procedures Manual for additional guidance on the final disposition of unused study
vaccines.
6.3. 
Measures to Minimize Bias: Randomization and Blinding
Study Vaccine Allocation
Procedures for Randomization
Central randomization will be implemented in this study. Participants will be randomly assigned
to 1 of 3 groups based on a computer-generated randomization schedule prepared before the study
by or under the supervision of the sponsor. The randomization will be balanced by using randomly
permuted blocks. The interactive web response system (IWRS) will assign a unique study vaccine
allocation code, which will dictate the study vaccine assignment and matching study vaccine kit
for the participant. The requestor must use their own user identification and personal identification
number when contacting the IWRS, and will then give the relevant participant details to uniquely
identify the participant.
Blinding
The investigator will not be provided with randomization codes until database lock of the final
analysis. The participants remain blinded until database lock of the final analysis. The codes will
be maintained within the IWRS, which has the functionality to allow the investigator to break the
blind for an individual participant.
For the sponsor, unblinding (at the participant level) will occur at the time of the primary analysis
(Section 9.5). From the primary analysis onwards, group level results may be shared as needed,
however, efforts will be made to preserve the blinding to the individual participant allocation.
Data that may potentially unblind the randomization group assignment (eg, immunogenicity data,
study vaccine preparation/accountability data, study vaccine allocation) will be handled with
special care to ensure that the integrity of the blind is maintained and the potential for bias is
minimized. This can include making special provisions, such as segregating the data in question
from view by the investigators, clinical team, or others as appropriate until the time of database
lock and unblinding.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
35
Status: Approved,Date: 26 November 2021
The investigator may in an emergency determine the identity of the randomization group by
contacting the IWRS. While the responsibility to break the study vaccine allocation code in
emergency situations resides solely with the investigator, it is recommended that the investigator
contacts the sponsor or its designee if possible,to discuss the particular situation, before breaking
the blind. Telephone contact with the sponsor or its designee will be available 24 hours per day,
7 days per week. In the event the blind is broken, the sponsor must be informed as soon as possible.
The date, time,and reason for the unblinding must be documented by the IWRS, in the appropriate
section of the eCRF, and in the source document. The documentation received from the IWRS
indicating the code break must be retained with the participant’s source documents in a secure
manner.
The study-site pharmacist or qualified individual with primary responsibility for study vaccine
preparation and dispensing will be unblinded to study vaccine allocation.
Participants who have had their randomization group assignment unblinded should continue to
return for scheduled evaluations.
Participants who withdraw will not be replaced.
6.4. 
Study Vaccination Compliance
Study vaccine will be administered IM by blinded qualified study-site personnel at the study site.
Details of each administration will be recorded in the eCRF (including date and time of injection,
and site of administration). For blinding procedures, see Section 6.3.
6.5. 
Dose Modification
Not applicable.
6.6. 
Continued Access to Study Vaccine After the End of the Study
Participants will be instructed that study vaccine will not be made available to them after they have
completed/discontinued study vaccination.
6.7. 
Treatment of Overdose
For this study, any dose ofthe Ad26/protein preF RSV vaccine greater than the protocol-specified
dose will be considered an overdose. The sponsor does not recommend specific treatment for an
overdose.
In the event of an overdose, the investigator or treating physician should:
 Contact the Medical Monitor immediately.
 Closely monitor the participant for AEs/SAEs/AESIs until resolution.
 Document the quantity of the excess dose in the eCRF.
 Report as a special reporting situation.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
36
Status: Approved,Date: 26 November 2021
6.8. 
Concomitant Therapy
Prestudy therapies administered within the 30 days before administration of the study vaccine must
be recorded on Day 1. Additionally, any history of SARS-CoV-2 vaccination (name/manufacturer
of the vaccine and date of administration, whenever possible) prior to and during the study will be
collected in the eCRF.
Concomitant therapies associated with solicited AEs will be collected by the participants in the
participant diary from the time of study vaccination through 7 days after vaccination. Concomitant
therapies associated with unsolicited AEs will be collected and recorded in the eCRF from the time
of study vaccination through 28 days after vaccination. Concomitant therapies associated with
SAEs or AESIs will be collected and recorded in the eCRF from ICF signature until 6 months after
vaccination.
Analgesic/antipyretic medications and non-steroidal anti-inflammatory drugs may be used post-
vaccination only in cases of medical need (eg, fever or pain) and their use must be documented.
Use of these medications as routine prophylaxis prior to study vaccination is discouraged.
Information on concomitant use of herbal supplements or vitamins will not be collected.
Use of any experimental medication (including experimental vaccines other than the study
vaccine) during the study is not allowed.
Vaccination with licensed live attenuated vaccines within 28 days of a study vaccination (ie, before
or after) is prohibited. Other licensed (not live) vaccines (eg, influenza, tetanus, hepatitis A,
hepatitis B, rabies) should be given at least 14 days before (or at least 14 days after) administration
of study vaccine in order to avoid potential confusion of adverse reactions and potential immune
interference. If a vaccine is indicated in a post-exposure setting (eg,rabies or tetanus), it must take
priority over the study vaccine.
For SARS-CoV-2 vaccines licensed or available under Emergency Use Authorization: live
attenuated vaccines should be given at least 28 days before or after vaccination; non-live vaccines
should be given at least 14 days before or after vaccination. A viral-vectored SARS-CoV-2 vaccine
is not to be given within 6 months prior to randomization or during the study period until 28 days
after the last study vaccination.
Use of systemic corticosteroidsa must be documented until 14 days after study vaccination.
Antineoplastic and immunomodulating agents, eg, cancer chemotherapeutic agents or systemic
corticosteroids, or radiotherapy are prohibited until 14 days after study vaccination. If the use of
systemic corticosteroids, antineoplastic or immunomodulating agents or any therapy described in
a Note: Ocular, topical, or inhaled steroids are allowed.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
37
Status: Approved,Date: 26 November 2021
exclusion criterion 7 becomes medically indicated during the study for any participant, the sponsor
should be notified.
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in
which prohibited therapies are administered.
7. 
DISCONTINUATION OF STUDY VACCINATION AND PARTICIPANT
DISCONTINUATION/WITHDRAWAL
7.1. 
Discontinuation of Study Vaccination
A participant’s study vaccination must be discontinued if:
 The participant withdraws consent to receive study vaccination.
 The investigator believes that for safety reasons or reactogenicity reasons (eg,AE) it is in the
best interest of the participant to discontinue study vaccination.
Study vaccine assigned to the participant who discontinued study vaccination may not be assigned
to another participant. Discontinuation of study vaccination is only possible between screening
and vaccination.
7.2. 
Participant Discontinuation/Withdrawal From the Study
A participant will be withdrawn from the study for any of the following reasons:
 Lost to follow-up
 Withdrawal of consent
 Death
 AnyAE that requires discontinuation from the study
 Repeated failure to comply with protocol requirements
When a participant withdraws before study  completion, the reason for withdrawal is to be
documented in the eCRF and in the source document. If the reason for withdrawal from the study
is withdrawal ofconsent then no additional assessments are allowed.
An early exit visit (by telephone) will be conducted for those participants who are unable to
continue participation in the study and withdraw from the study before Day 183, but who do not
withdraw consent (see Schedule of Activities). Participants who wish to withdraw consent from
participation in the study will be offered an early exit visit (prior to formal withdrawal of consent;
by telephone). They have the right to refuse.
Withdrawal of Consent
A participant declining to return for scheduled visits does not necessarily constitute withdrawal of
consent. Alternate follow-up mechanisms that the participant agreed to when signing the ICF apply

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
38
Status: Approved,Date: 26 November 2021
(eg, consult with family members, contacting the participant’s other physicians, medical records,
database searches, use of locator agencies at study completion)as local regulations permit.
7.2.1. 
Withdrawal From the Use of Research Samples
Withdrawal From the Use of Samples in Future Research
The participant may withdraw consent for use of samples for future research (refer to Long-Term
Retention of Samples for Additional Future Research in Appendix 3). In such a case, samples will
be destroyed after they are no longer needed for the clinical study. Details of the sample retention
for research are presented in the main ICF.
7.3. 
Lost to Follow-up
A participant will be considered lost to follow-up if the participant repeatedly fails to return for
scheduled visits and is unable to be contacted by the study site. A participant cannot be deemed
lost to follow-up until all reasonable efforts made by the study-site personnel to contact the
participant are deemed futile. The following actions must be taken if a participant fails to return to
the study site for a required study visit:
 The study-site personnel must attempt to contact the participant to reschedule the missed visit
as soon as possible, to counsel the participant on the importance of maintaining the assigned
visit schedule, to ascertain whether the participant wishes to or should continue in the study.
 Before a participant is deemed lost to follow-up, the investigator or designee must make every
reasonable effort to regain contact with the participant (where possible, 3 telephone calls,
e-mails, fax, and, if necessary, a certified letter to the participant’s last known mailing address,
or local equivalent methods. These contact attempts should be documented in the participant’s
medical records.
 Should the participant continue to be unreachable, they will be considered to have withdrawn
from the study.
Should a study site close, eg, for operational, financial, or other reasons, and the investigator cannot
reach the participant to inform them, their contact information will be transferred to another study
site.
8. 
STUDY ASSESSMENTS AND PROCEDURES
Overview
The Schedule of Activities summarizes the frequency and timing of study visits and of
immunogenicity and safety measurements applicable to this study.
If multiple assessments are scheduled for the same timepoint, it is recommended that procedures
be performed in the following sequence: vital signs, other safety assessments, blood draws. If
needed, assessments may be performed at another day within the applicable visit window. Actual
dates and times of assessments will be recorded in the source document and/or the eCRF.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
39
Status: Approved,Date: 26 November 2021
Participants will be provided a thermometer (to measure body temperature), ruler (to measure local
injection site reactions), and participant diary to record body temperature and solicited local
(injection site) and systemic signs and symptoms.
The participant diary includes instructions on how to capture the data and grading scales to assess
severity of the signs and symptoms. The study staff is responsible for providing appropriate
training to the participant to avoid missing or incorrect data. The participant diary will be reviewed
by the study-site personnel at the visit indicated in the Schedule of Activities.
The total blood volume to be collected from each participant will be approximately 30 mL.
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the
samples.
Visit Windows
For the following visits, windows will be allowed as indicated:
Clinic 
Visit # 
Visit 
Day  
Visit
Window  
Primary Purpose
3 
8 
± 2 days 
7 days after study vaccination, Safety visit, by telephone
4 
15 
-3 days / +7 days 14 days after study vaccination, Immunogenicity and Safety visit
5 
29 
± 7 days 
28 days after study vaccination, Safety visit, by telephone
6 
183 
± 14 days 
6 months after study vaccination, Immunogenicity and Safety visit
The timings of the post-vaccination visits will be determined relative to the actual day of study
vaccination.
Sample Collection and Handling
The actual dates and times of sample collection must be recorded in the eCRF or laboratory
requisition form.
Refer to the Schedule of Activities for the timing and frequency of all sample collections.
Instructions for the collection, handling, storage, and shipment of samples are found in the
laboratory manual that will be provided. Collection, handling, storage, and shipment of samples
must be under the specified, and where applicable, controlled temperature conditions as indicated
in the laboratory manual.
Study-Specific Materials
The investigator will be provided with the following supplies:
 IB for Ad26/protein preF RSV vaccine (IB Ad26/protein preF RSV vaccine 2021)
 Study Site Investigational Product and Procedures Manual
 Laboratory manual

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
40
Status: Approved,Date: 26 November 2021
 Investigational Product Preparation Instructions
 Participant diary and instructions for use
 Ruler (to measure diameter of any erythema and swelling)
 Thermometer
 Laboratory kits
 Contact Information page(s)
 Study protocol
 IWRS Manual
 Electronic data capture (eDC) Manual/eCRF completion guidelines
 Wallet card
 Sample ICF
8.1. 
Immunogenicity Assessments
Venous blood samples of approximately 10 mL will be collected for the determination of humoral
immune responses at the timepoints indicated in the Schedule of Activities. Sample collection and
processing will be performed by the study-site personnel according to current versions of approved
standard operating procedures.
The RSV A strain pre-F ELISA antibody titers are the primary (at Day 15) and exploratory (at
Month 6) endpoint for this study. In previous studies using the vaccine regimen, high pre-F ELISA
titers were commonly associated with high VNA-A2 titers following vaccination. 
 To complement the
pre-F ELISA responses and further characterize the functional antibody responses, RSV
neutralizing antibody responses (VNA-A2) will also be evaluated.
Humoral immunogenicity evaluations are summarized in Table 3.
Table 3: 
Summary of Immunogenicity Assays (Humoral)
Assay 
Purpose
Primaryand exploratory endpoints
F-protein antibodies 
(RSV-A pre-F ELISA)
Analysis of antibodies binding to RSV-A F-protein in pre-fusion form
Secondary and exploratory endpoints
RSV A neutralization assay (VNA 
A2)
Analysis of neutralizing antibodies against the RSV A2 strain
ELISA = enzyme-linked immunosorbent assay; VNA = virus neutralization assay
CCI

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
41
Status: Approved,Date: 26 November 2021
8.2. 
Safety Assessments
Safety assessments will include the monitoring of AEs and vital signs.
AEs will be reported and followed by the investigator as specified in Section 8.3 and Appendix 2.
Anyclinicallysignificantabnormalities will be followed by the investigator until clinical resolution
(return to baseline) or until a clinically stable condition is reached, or until the participant has been
deemed lost to follow-up after demonstration of due diligence of follow-up efforts.
The study will include the following evaluations of safety and reactogenicity according to the
timepoints provided in the Schedule of Activities.
8.2.1. 
Physical Examinations
At any clinic visit, an abbreviated, symptom-directed physical examination may be performed if
deemed necessary by the investigator based on any clinically relevant issues, clinically relevant
symptoms,and medical history.
Physical examinations will be performed by the investigator or appropriately trained delegate. Any
clinically relevant abnormalities or changes in severity noted during the review of body systems
should be documented in the eCRF as an AE or SAE if it meets the criteria for an AE or SAE
according to the protocol reporting requirements.
8.2.2. 
Vital Signs
Body temperature (oral route preferred), heart rate (beats per minute), respiratory rate (breaths per
minute), and systolic and diastolic blood pressure (mmHg) will be measured pre- and post-
vaccination. At non-vaccination visits, vital signs will be measured if deemed necessary by the
investigator. Height and weight will be measured during screening.
Blood pressure and heart rate measurements will be assessed, if possible, with a completely
automated device. Manual techniques will be used only if an automated device is not available.
Sitting systolic and diastolic blood pressure and heart and respiratory rate measurements should
be preceded by at least 5 minutes of rest in a quiet setting without distractions (eg, television, cell
phones).
Confirmatory vital signs measurement can be performed if inconsistent with a prior measurement.
Any abnormalities or changes in severity noted during the review of vital signs should be
documented in the eCRF.
8.3. 
AEs, SAEs, AESIs and Other Safety Reporting
Timely, accurate, and complete reporting and analysis of safety information, including AEs, SAEs,
AESIs (including potential AESIs, refer to Section 8.3.6) and Product Quality Complaints (PQCs),
from clinical studies are crucial for the protection of participants, investigators, and the sponsor,
and are mandated by regulatory agencies worldwide. The sponsor has established standard

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
42
Status: Approved,Date: 26 November 2021
operating procedures in conformity with regulatory requirements worldwide to ensure appropriate
reporting of safety information; all clinical studies conducted by the sponsor or its affiliates will
be conducted in accordance with those procedures.
AEs will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the
participant’s legally acceptable representative) for the duration of the study.
Further details on AEs,SAEs, AESIs, and PQCs can be found in Appendix 2.
8.3.1. 
Time Period and Frequency for Collecting AE, SAE, and AESI
Information
All AEs
AEs and special reporting situations, whether serious or non-serious, that are related to study
procedures or that are related to non-investigational sponsor products will be reported from the
time a signed and dated ICF is obtained until the end of the study/early withdrawal.
Clinically relevant medical events not meeting the above criteria and occurring between signing
of ICF and moment of vaccination will be collected on the Medical History eCRF page as
pre-existing conditions.
Solicited AEs, collected through a participant diary, will be recorded from the time of vaccination
until 7 days post-vaccination.
All other unsolicited AEs and special reporting situations, whether serious or non-serious, will be
reported from the time of vaccination until 28 days post-vaccination.
All SAEs and AEs leading to discontinuation from the study (regardless of the causal relationship)
are to be reported from the moment of vaccination until completion of the participant’s last study-
related procedure, which may include contact for safety follow-up. The sponsor will evaluate any
safety information that is spontaneously reported by an investigator beyond the time frame
specified in the protocol.
See Section 7.2 for procedures associated with withdrawal of consent.
All AEs will be followed until resolution or until clinically stable.
SAEs
All SAEs occurring during the study must be reported to the appropriate sponsor contact person
by study-site personnel immediately, but no later than 24 hours of their knowledge of the event.
Information regarding SAEs will be transmitted to the sponsor using the SAE Form and Safety
Report Form of the eCRF, which must be completed and reviewed by a physician from the study
site, and transmitted to the sponsor immediately but no later than within 24 hours. The initial and
follow-up reports of an SAE should be transmitted electronically or by facsimile (fax). Telephone

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
43
Status: Approved,Date: 26 November 2021
reporting should be the exception and the reporter should be asked to complete the appropriate
form(s) first.
AESIs
TTS is considered to be an AESI. Thrombotic events and/or thrombocytopenia (defined as platelet
count below the lower limit of normal [LLN] range for the testing lab) are considered to be
potential AESIs. All AESIs, including potential AESIs, will be reported to the sponsor from the
moment of study vaccination until 6 months after the study vaccination (see Section 8.3.6).
8.3.2. 
Method of Detecting AEs, SAEs and AESIs
Care will be taken not to introduce bias when detecting AEs, SAEs or AESIs. Open-ended and
nonleading verbal questioning of the participant is the preferred method to inquire about AE
occurrence.
Solicited AEs
Solicited AEs are used to assess the reactogenicity of the study vaccine and are predefined local
(injection site) and systemic events for which the participant is specifically questioned and which
are noted by participants in their participant diary.
After vaccination, participants will remain under observation at the study site for at least
15 minutes for presence of any acute reactions and solicited events.
In addition, participants will record solicited signs and symptoms in a participant diary for 7 days
post-vaccination. All participants will be provided with a participant diary and instructions on how
to complete the participant diary(see Overview in Section 8). If a paper diary is used for this study,
the study staff will transcribe the information provided by the participant into the relevant sections
of the eCRF. If an e-diary is used, diary information will be transferred to the sponsor. After review
and verbal discussion of the initial diary entries with the participant, the investigator will complete
their own assessment in the relevant sections of the eCRF. Once a solicited sign or symptom from
a participant diaryis considered to be of severity Grade 1 or above, it will be recorded as a solicited
AE.
Solicited Local (Injection Site)AEs
Participants will be asked to note in the participant diary  occurrences of injection site
pain/tenderness, erythema and swelling at the study vaccine injection site daily for 7 days post-
vaccination (day of vaccination and the subsequent 7 days). The extent (largest diameter) of any
erythema and swelling should be measured (using the ruler supplied) and recorded daily. The case
definitions for solicited injection site events can be found in the references (Gidudu 2012; Kohl
2007).
Solicited Systemic AEs
Participants will be instructed on how to record daily temperature using a thermometer provided
for home use. Participants should record the temperature (oral route preferred) in the participant

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
44
Status: Approved,Date: 26 November 2021
diary in the evening of the day of vaccination, and then daily for the next 7 days approximately at
the same time each day. If more than 1 measurement is made on any given day, the highest
temperature of that day will be used in the eCRF.
Fever is defined as endogenous elevation of body temperature ≥38.0°C (≥100.4°F), as recorded in
at least 1 measurement (Marcy 2004).
Participants will also be instructed on how to note signs and symptoms in the participant diary on
a daily basis for 7 days post-vaccination (day of vaccination and the subsequent 7 days), for the
following events: fatigue, headache, nausea, and myalgia.
Unsolicited AEs
Unsolicited AEs are all AEs for which the participant is not specifically questioned in the
participant diary.
For details regarding AESIs, refer to Section 8.3.6.
8.3.3. 
Follow-up of AEs, SAEs and AESIs
The investigator is obligated to perform or arrange for the conduct of supplemental measurements
and evaluations as medically indicated to elucidate the nature and causality of the AE, SAE, AESI,
or PQC as fully as possible. This may include additional laboratory tests or investigations,
histopathological examinations, or consultation with other health care professionals.
AEs and the special reporting situation of pregnancy, will be followed by the investigator as
specified in Appendix 2.
8.3.4. 
Regulatory Reporting Requirements for SAEs
The sponsor assumes responsibility for appropriate reporting of AEs to the regulatory authorities.
The sponsor will also report to the investigator (and the head of the investigational institute where
required) all suspected unexpected serious adverse reactions (SUSARs). The investigator (or
sponsor where required) must report SUSARs to the appropriate IEC/IRB that approved the
protocol unless otherwise required and documented by the IEC/IRB. A SUSAR will be reported to
regulatory authorities unblinded. Participating investigators and IEC/IRB will receive a blinded
SUSAR summary, unless otherwise specified.
8.3.5. 
Pregnancy
All initial reports of pregnancy in participants or partners of male participants must be reported to
the sponsor by the study-site personnel within 24 hours of their knowledge of the event using the
appropriate pregnancy notification form. Abnormal pregnancy outcomes (eg,spontaneous
abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs and
must be reported using an SAE reporting form.
If a participant becomes pregnant during the study, a determination regarding study vaccination
discontinuation must be made by the investigator in consultation with the sponsor. Follow-up

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
45
Status: Approved,Date: 26 November 2021
information regarding the outcome of the pregnancy will be required. If the partner of a male
participant becomes pregnant during the study, follow-up information regarding the outcome of
the pregnancy will be requested upon the consent provided by the partner.
8.3.6. 
Adverse Events of Special Interest
AESIs (including potential AESIs) are significant AEs that are judged to be of special interest
because of clinical importance, known or suspected class effects, or based on nonclinical signals.
AESIs and potential AESIs will be carefully monitored during the study by the sponsor.
AESIs and potential AESIs must be reported to the sponsor within 24 hours of awareness
irrespective of seriousness (ie, serious and nonserious AEs) or causality following the procedure
described above for SAEs.
AESIs must be reported using the AESI form in the eCRF using the eCRF completion guidelines.
Specific requirements for the AESI are described below.
8.3.6.1. 
Thrombosis with Thrombocytopenia Syndrome
As described in Section 2.2, TTS has been observed very rarely following vaccination with Janssen
COVID vaccine and is considered to be an AESI in this study. TTS is a syndrome characterized
by a combination of both a thrombotic event and thrombocytopenia. (American Society of
Hematology 2021; Brighton Collaboration 2021)
Because this syndrome is rare and not completely understood, all cases of thrombosis and/or
thrombocytopenia will be considered a potential case of TTS and should be reported to the sponsor
within 24 hours of awareness using the AESI form. Each potential AESI will be reviewed to
identify a TTS case. A potential TTS case is defined as:
 Thrombotic events: suspected deep vessel venous or arterial thrombotic events as detailed in
Section 10.6, Appendix 6,
and/or
 Thrombocytopenia, defined as platelet count below LLN for the testing lab
Symptoms, signs, or conditions suggestive of a thrombotic event or thrombocytopenia should be
recorded and reported as a potential AESI even if the final or definitive diagnosis has not yet been
determined, and alternative diagnoses have not yet been eliminated or shown to be less likely.
Follow-up information and final diagnoses, if applicable, should be submitted to the sponsor as
soon as they become available.
In the event of thrombocytopenia, study site personnel should report the absolute value for the
platelet count and the reference range for the laboratory test used.
For either a thrombotic event or thrombocytopenia, complete blood count including platelet count
and a coagulation profile available from participant’s medical records should be entered in the

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
46
Status: Approved,Date: 26 November 2021
eCRF. In case these results are not available at the time of the event report in the eCRF, the study
site is recommended to obtain a complete blood count including platelet count and a coagulation
profile (to be performed at the local laboratory). Repeat testing at the local laboratory may be
requested for confirmation upon sponsor discretion.
Aliquots of serum samples collected for immunogenicity tests can be reconverted for participant’s
safety purposes upon sponsor request (Table 4).
Table 4 provides non-exhaustive list(s) of laboratory tests that may be performed (upon sponsor
request).
In addition, the sponsor may request additional laboratory tests on additional blood samples
obtained as soon as possible after the potential AESI onset, either during an ad hoc unscheduled
visit or the next scheduled visit, whichever comes first. Table 5 provides a non-exhaustive list of
laboratory tests that may be requested by the sponsor in case of potential AESI reporting, for which
additional samples may be needed.
Table 4: 
Laboratory Tests That May Be Performed Upon Sponsor Request on Immunogenicity Samples
Collected on Day 1, 15, and/or 183 After Potential AESI Reporting
Parameters 
Timepoints
 Serum samples for assay such as but not limited to: 
o Heparin Induced Thrombocytopenia (HIT)/PF4 Ab, IgG·(HIT assay) 
If the above test is positive, also consider: 
 Anti-cardiolipin antibody 
 Beta-2 glycoprotein
 Days 1,15 and 183 visits
(aliquots of serum samples
collected for immunogenicity
test can be reconverted for
participant’s safety purposes).
Note: results of the test should be reported in the narrative of the event and/or in the TTS AESI pages of the eCRF.
Table 5: 
Laboratory Tests That May Be Requested by the Sponsor to be Performed at the Central
Laboratory After Potential AESI Reporting
Parameters 
Timepoints
 Serum/plasma/whole blood samples for coagulation-related assays such as 
but not limited to: 
o Fibrinogen 
o D-dimer· 
o Lupus anticoagulant· 
o Anti-cardiolipin antibody 
o Beta-2 glycoprotein·
o Heparin Induced Thrombocytopenia (HIT)/PF4 Ab, IgG·(HIT assay)
o Platelet activation assay (if HIT/PF4 is positive)
o Homocysteine·
o COVID-19 serological test
 As soon as possible after the
potential AESI onset upon
sponsor request (during an ad
hoc unscheduled visit or the
next scheduled visit, whichever
comes first).
Note: results of the test should be reported in the narrative of the event and/or in the TTS AESI pages of the eCRF.
Irrespective on samples for central laboratory tests collection, relevant data for TTS assessment reported in the
medical records of the participant should be reported in eCRF narrative of the event and/or in the TTS AESI pages
of the eCRF.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
47
Status: Approved,Date: 26 November 2021
AESIs, including potential AESIs, will require enhanced data collection and evaluation. Every
effort should be made to report as much information as possible about the event to the sponsor in
a reasonable timeframe. Relevant laboratory results can be entered on the AESI form in the eCRF,
using the eCRF completion guidelines.
If the investigator is not the treating physician, every effort should be made to collect the
information requested in the form from the treating physician and enter the available information
in the eCRF.
If an event meets the criteria for an SAE (Section 10.2.1), it should be reported using the same
process as for other SAEs.
Treatment and Follow-up Recommendation
The medical management of thrombotic events with thrombocytopenia is different from the
management of isolated thromboembolic diseases. Study site personnel and/or treating physicians
should follow available guidelines for treatment of thrombotic thrombocytopenia (eg, American
Society of Hematology 2021; British Society of Haematology 2021; CDC 2021). The use of
heparin may be harmful and alternative treatments may be needed. Consultation with a
hematologist is strongly recommended.
8.4. 
Medical Resource Utilization
Medical Resource Utilization parameters are not evaluated in this study.
9. 
STATISTICAL CONSIDERATIONS
Statistical analysis will be done by the sponsor or under the authority of the sponsor. A general
description of the statistical methods to be used to analyze the immunogenicity and safety data is
outlined below. Specific details will be provided in the Statistical Analysis Plan (SAP).
9.1. 
Statistical Hypotheses
For a description of the hypotheses, see Section 3.
Non-inferiority of Group 2 versus Group 1 is demonstrated if the 2-sided 95% CI for the GMR
(GMTGroup 2/GMTGroup 1) of the Day 15 pre-F ELISA titers lies entirely above 0.67. If
non-inferiority of Group 2 versus Group 1 is not demonstrated, the study fails. If non-inferiority
of Group 2 versus Group 1 is demonstrated, then non-inferiority of Group 3 versus Group 1 can
be tested: similarly, non-inferiority of Group 3 versus Group 1 is demonstrated if the 2-sided 95%
CI for the GMR (GMTGroup 3/GMTGroup 1) of the Day 15 pre-F ELISA titers lies entirely above 0.67.
9.2. 
Sample Size Determination
Sample size calculations are performed under the following assumptions:
 a 10% decrease in GMT of the groups with aged lots (Group 2 and Group 3) versus the group
with the non-aged lot (Group 1) (ie, assuming a true GMR of Day 15 pre-F ELISA titers equal
to 0.9)

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
48
Status: Approved,Date: 26 November 2021
 a standard deviation of 1.3 at the log2 scale for pre-F ELISA on Day 15a
 a non-inferiority margin of 0.67 (2/3)
 a 2-sided αof 5%
 hierarchical testing (ie, first Group 2 versus Group 1; if non-inferiority is demonstrated, then
Group 3 versus Group 1)
A total of 236 evaluable participants per group are needed to have 95% power to demonstrate non-
inferiority for each comparison separately. With this sample size, the overall power to demonstrate
non-inferiority of Group 3 versus Group 1 as the second comparison in the hierarchy is at least
90%.
To account for exclusions from the Per-protocol Immunogenicity (PPI) Set (see Section 9.3 for
the definitions of the analysis sets), dropouts,and missing samples, approximately 250 participants
per group should be enrolled.
9.3. 
Populations for Analysis Sets
Vaccination assignment will follow the as-treated principle.
The Full Analysis (FA)Set will include all participants who received study vaccine, regardless of
the occurrence of protocol deviations. All safety and participant information analyses will be based
on the FA Set.
The PPI Set will include all randomized participants who received study vaccine and for whom
immunogenicity data are available. Samples taken after a participant experiences a major protocol
deviation expected to impact the immunogenicity outcomes will be excluded from the PPI
analysis.
The list of major protocol deviations that would lead to elimination from the immunogenicity
analysis will be specified in the SAP or major protocol violation criteria document, which will be
finalized before database lock and unblinding.
The primary analysis set for analyses related to RSV immunogenicity is the PPI Set. As a
sensitivity analysis, key tables may also be based on the FA Set.
9.4. 
Statistical Analyses
The SAP will be finalized prior to database lock of the primary analysis and it will include a more
technical and detailed description of the statistical analyses described in this section. This section
is a summary of the planned statistical analyses of the key endpoints.
a Based on the standard deviation of pre-F ELISA at 14 days after vaccine administration observed in Group 14 of
study VAC18193RSV1004.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
49
Status: Approved,Date: 26 November 2021
9.4.1. 
General Considerations
The primary analysis will be performed when all participants have completed the visit 28 days
post-vaccination or discontinued earlier.
The significance level (α) is 5% (2-sided). As the 2 primary objectives are tested sequentially and
as no interim analyses before the primary analysis are planned, no multiplicity adjustments are
needed.
Refer to Section 9.3 for the choice of populations for the different analyses.
9.4.2. 
Participant Information
For all participants, demographic characteristics (eg, age, height, body weight, body mass index,
race, and gender) and other baseline characteristics will be tabulated and summarized descriptively
by group.
9.4.3. 
Immunogenicity Analyses
9.4.3.1. 
Primary Endpoints
The primary immunogenicity objective will be assessed by calculating the 2-sided 95% CIs for the
difference in log-transformed Day 15 pre-F ELISA titers for each of the comparisons (ie, Group 2
versus Group 1, and Group 3 versus Group 1).
The CIs will be calculated via an analysis of variance (ANOVA) including all groups (ie, Groups 1
to 3) with the log-transformed Day 15 pre-F ELISA titers as dependent variable and group as
independent variable. The CIs around the difference will be back-transformed (by exponentiation)
to CIs around a GMR (GMTGroup x/GMTGroup 1 where x is 2 or 3) and compared to the
non-inferiority margin of 0.67 (2/3).
Non-inferiority of Group 2 versus Group 1 is demonstrated if the 2-sided 95% CI for the GMR
(GMTGroup 2/ GMTGroup 1) of the Day 15 pre-F ELISA titers lies entirely above 0.67. If non-
inferiority of Group 2 versus Group 1 is not demonstrated, the study fails. If non-inferiority of
Group 2 versus Group 1 is demonstrated, then non-inferiority of Group 3 versus Group 1 can be
tested: similarly, non-inferiority of Group 3 versus Group 1 is demonstrated if the 2-sided 95% CI
for the GMR (GMTGroup 3/GMTGroup 1) of the Day 15 pre-F ELISA titers lies entirely above 0.67.
As a sensitivity analysis to assess the impact of baseline titers, the primary endpoint will also be
evaluated adjusting for the respective baseline titers. For immunogenicity, baseline is considered
as the last assessment pre-vaccination. In a second sensitivity analysis, different variances between
the study groups will be allowed. Therefore, the CIs will be calculated via Welch’s ANOVA.
The pre-F ELISA titers will be summarized descriptively. For continuous parameters, descriptive
statistics of the actual values (geometric mean and 95% CI) will be calculated at all timepoints.
Additionally, geometric mean fold increases from baseline and corresponding 95% CIs will be

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
50
Status: Approved,Date: 26 November 2021
calculated. Graphical representations of immunogenicity parameters will be created as applicable.
For categorical variables, frequency tables will be presented.
9.4.3.2. 
Secondary and Exploratory Endpoints
No formal statistical testing of the secondary and exploratory immunogenicity endpoints is
planned. These data will be analyzed descriptively by group. Descriptive statistics (eg, geometric
mean and 95% CI) will be calculated for continuous immunogenicity parameters at all timepoints.
Geometric mean fold rises from baseline and corresponding 95% CIs may also be calculated.
Baseline is considered the last available assessment prior to vaccination. Graphical displays of
immunogenicity parameters will be prepared, as applicable. GMRs (GMTGroup 2/GMTGroup 1 and
GMTGroup 3/GMTGroup 1) will also be calculated for VNA A2 in a similar manner as for pre-F
ELISA. Frequency tabulations will be calculated for discrete (qualitative) immunogenicity
parameters, as applicable.
9.4.4. 
Safety Analyses
No formal statistical testing of safety data is planned. All safety data will be analyzed descriptively
by group. All safety analyses will be based on the FA Set.
AEs
The verbatim terms used in the eCRF by investigators to identify AEs will be coded using the
Medical Dictionary for Regulatory Activities (MedDRA). All reported AEs with onset during the
active phase (ie, AEs occurring from the time ofvaccination up to 28 days post-vaccination), and
all SAEs and AESIs will be included in the analysis. For each AE, the number and percentage of
participants who experience at least 1 occurrence of the given event will be summarized by group.
Summaries, listings, datasets, or participant narratives may be provided, as appropriate, for those
participants who die, who discontinue study vaccination due to an AE, or who experience a severe
AE,an SAE or an AESI.
Summaries and/or listings may be provided separately for AEs with onset outside the above
defined timeframe (ie, beyond 28 days post-vaccination).
Solicited local (injection site) and systemic AEs will be summarized descriptively. The overall
frequencies per group as well as frequencies according to severity and duration will be calculated
for solicited AEs. In addition, the number and percentages of participants with at least 1 solicited
local (injection site) or systemic AE will be presented. Frequencies of unsolicited AEs, separately
for all and vaccination-related only, will be presented by System Organ Class and Preferred Term.
Vital Signs
Baseline and emerging vital signs abnormalities will be listed.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
51
Status: Approved,Date: 26 November 2021
9.5. 
Planned Analyses
The following analyses are planned:
 Primary analysis: including safety and immunogenicity data up to 28 days post-vaccination.
This analysis will be performed based on sponsor unblinded data (study-site personnel and
participants will remain blinded until the end of the study).
 Final analysis: including SAE data up to study end and immunogenicity data up to Day 183.
This analysis will be performed on unblinded data.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
52
Status: Approved,Date: 26 November 2021
10. 
SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Abbreviations
Ad26 
adenovirus serotype 26
AE 
adverse event
AESI 
adverse event of special interest
ANOVA  
analysis of variance
CI 
confidence interval
COVID-19 
coronavirus disease-2019
CTM  
Clinical Trial Manager
CVST  
cerebral venous sinus thrombosis
DNA  
deoxyribonucleic acid
DMC  
Data Monitoring Committee
eCRF  
electronic case report form
eDC  
electronic data capture
ELISA  
enzyme-linked immunosorbent assay
FA 
Full Analysis
FDA  
(United States) Food and Drug Administration
FOIA  
Freedom of Information Act
GCP  
Good Clinical Practice
GMR  
geometric mean titer ratio
GMT  
geometric mean titer
HITT  
heparin-induced thrombocytopenia and thrombosis
HIV  
human immunodeficiency virus
IB  
Investigator’s Brochure
ICF  
informed consent form
ICH  
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for
Human Use
ICMJE 
International Committee of Medical Journal Editors
IEC  
Independent Ethics Committee
IM  
intramuscular
IRB  
Institutional Review Board
IWRS  
interactive web response system
LLN  
lower limit of normal
LTM  
Local Trial Manager
MedDRA  
Medical Dictionary for Regulatory Activities
PCC  
protocol clarification communication
PPI 
Per-protocol Immunogenicity
PQC  
Product Quality Complaint
pre-F 
prefusion conformation-stabilized F protein
RSV  
respiratory syncytial virus
SAE 
serious adverse event
SAP  
statistical analysis plan
SARS-CoV-2 
Severe Acute Respiratory Syndrome Coronavirus-2
SUSAR  
suspected unexpected serious adverse reaction
TTS  
thrombosis with thrombocytopenia syndrome
vp 
viral particles

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
53
Status: Approved,Date: 26 November 2021
10.2. Appendix 2: AEs, SAEs, AESIs, PQCs, and Other Safety Reporting:
Definitions and Procedures for Recording, Evaluating, Follow-up, and
Reporting
10.2.1. 
AE Definitions and Classifications
AE
An AE is any untoward medical occurrence in a clinical study participant administered a
pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have
a causal relationship with the study vaccine. An AE can therefore be any unfavorable and
unintended sign (including an abnormal finding), symptom, or disease temporally associated with
the use of a medicinal (investigational or non-investigational) product, whether or not related to
that medicinal (investigational or non-investigational) product. (Definition per International
Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [ICH])
This includes any occurrence that is new in onset or aggravated in severity or frequency from the
baseline condition, or abnormal results of diagnostic procedures, including laboratory test
abnormalities.
Note: For time period of sponsor’s AE collection, see All AEs under Section 8.3.1, Time Period
and Frequency for Collecting AE and SAE Information.
SAE
An SAE based on ICH and European Union  Guidelines on Pharmacovigilance for Medicinal
Products for Human Use is any untoward medical occurrence that at any dose:
 Results in death
 Is life-threatening
(The participant was at risk of death at the time of the event. It does not refer to an event that
hypothetically might have caused death if it were more severe.)
 Requires inpatient hospitalization or prolongation of existing hospitalization
 Results in persistent or significant disability/incapacity
 Is a congenital anomaly/birth defect
 Is a suspected transmission of any infectious agent via a medicinal product
 Is Medically Important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is
also appropriate in other situations, such as important medical events that may not be immediately
life threatening or result in death or hospitalization but may jeopardize the participant or may
require intervention to prevent one of the other outcomes listed in the definition above. These
should usually be considered serious.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
54
Status: Approved,Date: 26 November 2021
If a serious and unexpected AE occurs for which there is evidence suggesting a causal relationship
between the study vaccine and the event (eg, death from anaphylaxis), the event must be reported
as a SUSAR by the sponsor to health authorities and by the investigator to the IEC/IRB according
to regulatory and local requirements.
Unlisted (Unexpected) AE/Reference Safety Information
An AE is considered unlisted if the nature or severity is not consistent with the applicable product
reference safety information. For the Ad26/protein preF RSV vaccine, the expectedness of an AE
will be determined by whether or not it is listed in the IB (IB Ad26/protein preF RSV vaccine
2021).
10.2.2. 
Attribution Definitions
Assessment of Causality
The causal relationship to study vaccine is determined by the investigator. The following selection
should be used to assess all AEs.
Related
There is a reasonable causal relationship between study vaccine administration and the AE.
Not Related
There is not a reasonable causal relationship between study vaccine administration and the AE.
The term "reasonable causal relationship" means there is evidence to support a causal relationship.
By definition, all solicited AEs at the injection site (local) will be considered related to the study
vaccine administration.
10.2.3. 
Severity Criteria
All AEs will be coded for severity using a modified version of the FDA grading table, based on
the version of September 2007 (FDA 2007), included in Appendix 4, Toxicity Grading Scale.
For AEs not identified in the grading table, the following guidelines will be applied:

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
55
Status: Approved,Date: 26 November 2021
Grade 1 Mild 
Symptoms causing no or minimal interference with usual social
and functional activities
Grade 2 Moderate 
Symptoms causing greater than minimal interference with usual
social and functional activities
Grade 3 Severe 
Symptoms causing inability to perform usual social and
functional activities and requiring medical intervention
Grade 4 Potentially 
life-threatening 
Symptoms causing inability to perform basic self-care
functions OR medical or operative intervention indicated to
prevent permanent impairment, persistent disability OR
emergency room visit or hospitalization
The severity of solicited signs and symptoms will be graded in the participant diary by the
participant based on the severity assessment provided in the participant diary and then verified by
the investigator using the toxicity grading scale in Appendix 4. (Note: severity of the measured
events will be derived from the diameter [for erythema and swelling] and the temperature
measurements [for fever])
10.2.4. 
Special Reporting Situations
Safety events of interest for a sponsor study vaccine in an interventional study that may require
expedited reporting or safety evaluation include, but are not limited to:
 Overdose of a sponsor study vaccine
 Suspected abuse/misuse of a sponsor study vaccine
 Accidental or occupational exposure to a sponsor study vaccine
 Medication error, intercepted medication error, or potential medication error involving a
Johnson & Johnson medicinal product (with or without patient exposure to the Johnson &
Johnson medicinal product, eg, product name confusion, product label confusion, intercepted
prescribing or dispensing errors)
 Exposure to a sponsor study vaccine from breastfeeding
 Reporting of participant pregnancy or participant partner(s) pregnancy
Special reporting situations should be recorded in the eCRF. Any special reporting situation that
meets the criteria of an SAE should be recorded on the SAE page of the eCRF.
10.2.5. 
Procedures
All AEs
All AEs, regardless of seriousness, severity, or presumed relationship to study vaccine, must be
recorded using medical terminology in the source document and the eCRF. Whenever possible,
diagnoses should be given when signs and symptoms are due to a common etiology (eg,cough,

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
56
Status: Approved,Date: 26 November 2021
runny nose, sneezing, sore throat, and head congestion should be reported as “upper respiratory
infection”). Investigators must record in the eCRF their opinion concerning the relationship of the
AE to study vaccine. All measures required for AE management must be recorded in the source
document and reported according to sponsor instructions.
For all studies with an outpatient phase, including open-label studies, the participant must be
provided with a "wallet (study) card" and instructed to carry this card with them for the duration
of the study indicating the following:
 Study number
 Statement, in the local language(s), that the participant is participating in a clinical study
 Investigator’s name and 24-hour contact telephone number
 Local sponsor’s name and 24-hour contact telephone number (for medical personnel only)
 Site number
 Participant number
 Any other information that is required to do an emergency breaking of the blind
SAEs
All SAEs that have not resolved by the end of the study, or that have not resolved upon the
participant’s discontinuation from the study, must be followed until any of the following occurs:
 The event resolves
 The event stabilizes
 The event returns to baseline, if a baseline value/status is available
 The event can be attributed to agents other than the study vaccine or to factors unrelated to
study conduct
 It becomes unlikely that any additional information can be obtained (participant or health care
practitioner refusal to provide additional information, lost to follow-up after demonstration of
due diligence with follow-up efforts)
Any event requiring hospitalization (or prolongation of hospitalization) that occurs during
participation in the study must be reported as an SAE, except hospitalizations for the following:
 Hospitalizations not intended to treat an acute illness or AE (eg, social reasons such as pending
placement in long-term care facility).
 Surgery or procedure planned before entry into the study (must be documented in the eCRF).
Note: Hospitalizations that were planned before the signing of the ICF, and where the
underlying condition for which the hospitalization was planned has not worsened, will not be
considered SAEs. Any AE that results in a prolongation of the originally planned
hospitalization is to be reported as a new SAE.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
57
Status: Approved,Date: 26 November 2021
The cause of death of a participant in a study during the entire study period, whether or not the
event is expected or associated with the study vaccine, is considered an SAE and must be reported.
Information regarding SAEs will be transmitted to the sponsor using an SAE reporting form and
safety report form of the eCRF, which must be completed and reviewed by a physician from the
study site, and transmitted in a secure manner to the sponsor within 24 hours. The initial and
follow-up reports of an SAE should be transmitted in a secure manner electronically or by
facsimile (fax). Telephone reporting should be the exception and the reporter should be asked to
complete the appropriate form(s) first.
Adverse Events of Special Interest
AESIs, including potential AESIs, will be carefully monitored during the study by the sponsor and
must be reported to the sponsor within 24 hours of awareness irrespective of seriousness (ie,
serious and nonserious AEs) or causality assessment, following the procedure described above for
SAEs and will require enhanced data collection.
10.2.6. 
PQC Handling
Definition
A PQC is defined as any suspicion of a product defect related to manufacturing, labeling, or
packaging, ie, any dissatisfaction relative to the identity, quality, durability, reliability, or
performance of a distributed product, including its labeling, drug delivery system, or package
integrity. A PQC may have an impact on the safety and efficacy of the product. In addition, it
includes any technical complaints, defined as any complaint that indicates a potential quality issue
during manufacturing, packaging, release testing, stability monitoring, dose preparation, storage
or distribution of the product or the drug delivery system.
All complaints related to ANY part of the Ad26/protein preF RSV vaccine must be reported within
1 business day. In the event of public holiday, measures must be taken to ensure reporting no later
than calendar day 3.
Procedures
All initial PQCs must be reported to the sponsor by the study-site personnel within 24 hours after
being made aware of the event.
A sample of the suspected product should be maintained under the correct storage conditions until
a shipment request is received from the sponsor.
10.2.7. 
Contacting Sponsor Regarding Safety, Including Product Quality
The names (and corresponding telephone numbers) of the individuals who should be contacted
regarding safety issues, PQC, or questions regarding the study are listed in the Contact Information
page(s), which will be provided as a separate document.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
58
Status: Approved,Date: 26 November 2021
10.3. Appendix 3: Regulatory, Ethical, and Study Oversight Considerations
10.3.1. 
Regulatory and Ethical Considerations
Investigator Responsibilities
The investigator is responsible for ensuring that the study is performed in accordance with the
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory and
country-specific requirements.
GCPis an international ethical and scientific quality standard for designing, conducting, recording,
and reporting studies that involve the participation of human participants. Compliance with this
standard provides public assurance that the rights, safety, and well-being of study participants are
protected, consistent with the principles that originated in the Declaration of Helsinki, and that the
study data are credible.
Protocol Clarification Communications
If text within a final approved protocol requires clarification (eg, current wording is unclear or
ambiguous) that does not change any aspect of the current study conduct, a protocol clarification
communication (PCC) may be prepared. The PCC Document will be communicated to the
Investigational Site, Site Monitors, Local Trial Managers (LTMs), Clinical Trial Managers
(CTMs), and/or Contract Research Organizations (CROs) who will ensure that the PCC
explanations are followed by the investigators.
The PCC Document may be shared by the sites with Independent Ethics Committees/Institutional
Review Boards (IECs/IRBs) per local regulations.
The PCC Documents must NOT be used in place of protocol amendments, but the content of the
PCC Document must be included in any future protocol amendments.
Protocol Amendments
Neither the investigator nor the sponsor will modify this protocol without a formal amendment by
the sponsor. All protocol amendments must be issued by the sponsor, and signed and dated by the
investigator. Protocol amendments must not be implemented without prior IEC/IRB approval, or
when the relevant competent authority has raised any grounds for non-acceptance, except when
necessary to eliminate immediate hazards to the participants, in which case the amendment must
be promptly submitted to the IEC/IRB and relevant competent authority. Documentation of
amendment approval by the investigator and IEC/IRB must be provided to the sponsor. When the
change(s) involve only logistic or administrative aspects of the study, the IEC/IRB (where
required) only needs to be notified.
During the study, in situations where a departure from the protocol is unavoidable, the investigator
or other physician in attendance will contact the appropriate sponsor representative listed in the
Contact Information page(s), which will be provided as a separate document. Except in emergency
situations, this contact should be made before implementing any departure from the protocol. In

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
59
Status: Approved,Date: 26 November 2021
all cases, contact with the sponsor must be made as soon as possible to discuss the situation and
agree on an appropriate course of action. The data recorded in the eCRF and source documents
will reflect any departure from the protocol, and the source documents will describe this departure
and the circumstances requiring it.
Regulatory Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory authorities
in each respective country, if applicable. A study may not be initiated until all local regulatory
requirements are met.
Required Prestudy Documentation
The following documents must be provided to the sponsor before shipment of study vaccine to the
study site:
 Protocol and amendment(s), if any, signed and dated by the principal investigator
 A copy of the dated and signed (or sealed, where appropriate per local regulations), written
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if
applicable, participant compensation programs. This approval must clearly identify the
specific protocol by title and number and must be signed (or sealed, where appropriate per
local regulations) by the chairman or authorized designee.
 Name and address of the IEC/IRB, including a current list of the IEC/IRB members and their
function, with a statement that it is organized and operates according to GCP and the
applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, from
the IEC/IRB, a general statement may be substituted for this list. If an investigator or a
member of the study-site personnel is a member of the IEC/IRB, documentation must be
obtained to state that this person did not participate in the deliberations or in the vote/opinion
of the study.
 Regulatory authority approval or notification, if applicable
 Signed and dated statement of investigator (eg,Form FDA 1572), if applicable
 Documentation of investigator qualifications (eg,curriculum vitae)
 Completed investigator financial disclosure form from the principal investigator, where
required
 Signed and dated clinical trial agreement, which includes the financial agreement
 Any other documentation required by local regulations
The following documents must be provided to the sponsor before enrollment of the first
participant:
 Completed investigator financial disclosure forms from all sub-investigators
 Documentation of sub-investigator qualifications (eg,curriculum vitae)

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
60
Status: Approved,Date: 26 November 2021
 Name and address of any local laboratory conducting tests for the study, and a dated copy of
current laboratory normal ranges for these tests, if applicable
 Local laboratory documentation demonstrating competence and test reliability
(eg,accreditation/license), if applicable
IEC or IRB
Before the start of the study, the investigator (or sponsor where required) will provide the IEC/IRB
with current and complete copies of the following documents (as required by local regulations):
 Final protocol and, if applicable, amendments
 Sponsor-approved ICF (and any other written materials to be provided to the participants)
 IB (or equivalent information) and amendments/addenda
 Sponsor-approved participant recruiting materials
 Information on compensation for study-related injuries or payment to participants for
participation in the study, if applicable
 Investigator’s curriculum vitae or equivalent information (unless not required, as documented
by the IEC/IRB)
 Information regarding funding, name of the sponsor, institutional affiliations, other potential
conflicts of interest, and incentives for participants
 Any other documents that the IEC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/IRB has given full approval of the final protocol,
amendments (if any, excluding the ones that are purely administrative, with no consequences for
participants, data or study conduct, unless required locally), the ICF, applicable recruiting
materials, and participant compensation programs, and the sponsor has received a copy of this
approval. This approval letter must be dated and must clearly identify the IEC/IRB and the
documents being approved.
During the study the investigator (or sponsor where required) will send the following documents
and updates to the IEC/IRB for their review and approval, where appropriate:
 Protocol amendments (excluding the ones that are purely administrative, with no
consequences for participants, data or study conduct)
 Revision(s) to ICF and any other written materials to be provided to participants
 If applicable, new or revised participant recruiting materials approved by the sponsor
 Revisions to compensation for study-related injuries or payment to participants for
participation in the study, if applicable
 New edition(s) of the IB and amendments/addenda
 Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at
least annually)

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
61
Status: Approved,Date: 26 November 2021
 Reports of AEs that are serious, unlisted/unexpected, and associated with the study vaccine
 New information that may adversely affect the safety of the participants or the conduct of the
study
 Deviations from or changes to the protocol to eliminate immediate hazards to the participants
 Report of deaths of participants under the investigator’s care
 Notification if a new investigator is responsible for the study at the site
 Development Safety Update Report and Line Listings, where applicable
 Any other requirements of the IEC/IRB
For all protocol amendments (excluding the ones that are purely administrative, with no
consequences for participants, data or study conduct), the amendment and applicable ICF revisions
must be submitted promptly to the IEC/IRB for review and approval before implementation of the
change(s).
At least once a year, the IEC/IRB will be asked to review and reapprove this study, where required.
At the end of the study, the investigator (or sponsor where required) will notify the IEC/IRB about
the study completion.
Country Selection
This study will only be conducted in those countries where the intent is to launch or otherwise help
ensure access to the developed product if the need for the product persists, unless explicitly
addressed as a specific ethical consideration in Section 4.2.1, Study-Specific Ethical Design
Considerations.
Other Ethical Considerations
For study-specific ethical design considerations, refer to Section 4.2.1.
10.3.2. 
Financial Disclosure
Investigators and sub-investigators will provide the sponsor with sufficient, accurate financial
information in accordance with local regulations to allow the sponsor to submit complete and
accurate financial certification or disclosure statements to the appropriate regulatory authorities.
Investigators are responsible for providing information on financial interests during the study and
for 1 year after completion of the study.
Refer to Required Prestudy Documentation (above) for details on financial disclosure.
10.3.3. 
Informed Consent Process
Each participant must give written consent according to local requirements after the nature of the
study has been fully explained. The ICF(s) must be signed before performance of any study-related
activity. The ICF(s) that is/are used must be approved by both the sponsor and by the reviewing

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
62
Status: Approved,Date: 26 November 2021
IEC/IRB and be in a language that the participant can read and understand. The informed consent
should be in accordance with principles that originated in the Declaration of Helsinki, current ICH
and GCP guidelines, applicable regulatory requirements, and sponsor policy.
Before enrollment in the study, the investigator or an authorized member of the study-site
personnel must explain to potential participants the aims, methods, reasonably anticipated benefits,
and potential hazards of the study, and any discomfort participation in the study may entail.
Participants will be informed that their participation is voluntary and that they may withdraw
consent to participate at any time. They will be informed that choosing not to participate will not
affect the care the participant will receive. Finally, they will be told that the investigator will
maintain a participant identification register for the purposes of long-term follow-up if needed and
that their records may be accessed by health authorities and authorized sponsor personnel without
violating the confidentiality of the participant, to the extent permitted by the applicable law(s) or
regulations. By signing the ICF the participant is authorizing such access. It also denotes that the
participant agrees to allow the study physician to recontact the participant for the purpose of
obtaining consent for additional safety evaluations, if needed.
The participant will be given sufficient time to read the ICF and the opportunity to ask questions.
After this explanation and before entry into the study, consent should be appropriately recorded by
means of the participant’s personally dated signature. After having obtained the consent, a copy of
the ICF must be given to the participant.
Participants who are rescreened are required to sign a new ICF.
If the participant is unable to read or write, an impartial witness should be present for the entire
informed consent process (which includes reading and explaining all written information) and
should personally date and sign the ICF after the oral consent of the participant is obtained.
10.3.4. 
Data Protection
Privacy of Personal Data
The collection and processing of personal data from participants enrolled in this study will be
limited to those data that are necessary to fulfill the objectives of the study.
These data must be collected and processed with adequate precautions to ensure confidentiality
and compliance with applicable data privacy protection laws and regulations. Appropriate
technical and organizational measures to protect the personal data against unauthorized disclosures
or access, accidental or unlawful destruction, or accidental loss or alteration must be put in place.
Sponsor personnel whose responsibilities require access to personal data agree to keep the identity
of participants confidential.
The informed consent obtained from the participant includes explicit consent for the processing of
personal data and for the investigator/institution to allow direct access to their original medical
records (source data/documents) for study-related monitoring, audit, IEC/IRB review, and

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
63
Status: Approved,Date: 26 November 2021
regulatory inspection. This consent also addresses the transfer of the data to other entities and to
other countries.
The participant has the right to request through the investigator access to their personal data and
the right to request rectification of any data that are not correct or complete. Reasonable steps will
be taken to respond to such a request, taking into consideration the nature of the request, the
conditions of the study, and the applicable laws and regulations.
10.3.5. 
Long-Term Retention of Samples for Additional Future Research
Samples collected in this study may be stored for up to 15 years (or according to local regulations)
for additional research. Samples will only be used to understand Ad26.RSV.preF and RSV preF
protein, to understand RSV and other respiratory pathogens, and to develop tests/assays related to
Ad26.RSV.preF, RSV preF protein,and RSV disease. The research may begin at any time during
the study or the post-study storage period. Included are samples from participants who were
screened but not randomized, and which may also be used to develop tests/assays related to
Ad26.RSV.preF, RSV preF protein, and RSV disease.
Stored samples will be coded throughout the sample storage and analysis process and will not be
labeled with personal identifiers. Participants may withdraw their consent for their samples to be
stored for research (refer to Section 7.2.1, Withdrawal From the Use of Research Samples).
10.3.6. 
Committees Structure
Safety issues that might arise from this study may be escalated to an independent DMC,as needed.
All potential AESI cases will be reviewed to determine if they meet the definition of TTS (see
Section 8.3.6.1). A Charter will be developed to describe the roles and responsibilities of the
Committee appointed to perform this review.
10.3.7. 
Publication Policy/Dissemination of Clinical Study Data
All information, including but not limited to information regarding the Ad26/protein preF RSV
vaccine or the sponsor’s operations (eg,patent application, formulas, manufacturing processes,
basic scientific data, prior clinical data, formulation information) supplied by the sponsor to the
investigator and not previously published, and any data, generated as a result of this study, are
considered confidential and remain the sole property of the sponsor. The investigator agrees to
maintain this information in confidence and use this information only to accomplish this study and
will not use it for other purposes without the sponsor’s prior written consent.
The investigator understands that the information developed in the study will be used by the
sponsor in connection with the continued development ofthe Ad26/protein preF RSV vaccine, and
thus may be disclosed as required to other clinical investigators or regulatory agencies. To permit
the information derived from the clinical studies to be used, the investigator is obligated to provide
the sponsor with all data obtained in the study.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
64
Status: Approved,Date: 26 November 2021
The results of the study will be reported in a clinical study report generated by the sponsor and
will contain data from all study sites that participated in the study as per protocol. Recruitment
performance or specific expertise related to the nature and the key assessment parameters of the
study will be used to determine a coordinating investigator for the study. Results of analyses
performed after the clinical study report has been issued will be reported in a separate report and
will not require a revision of the clinical study report.
Study participant identifiers will not be used in publication of results. Any work created in
connection with performance of the study and contained in the data that can benefit from copyright
protection (except any publication by the investigator as provided for below) shall be the property
of the sponsor as author and owner of copyright in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal
Editors (ICMJE) guidelines, the sponsor shall have the right to publish such primary (multicenter)
data and information without approval from the investigator. The investigator has the right to
publish study site-specific data after the primary data are published. If an investigator wishes to
publish information from the study, a copy of the manuscript must be provided to the sponsor for
review at least 60 days before submission for publication or presentation. Expedited reviews will
be arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in
writing, the investigator will withhold such publication for up to an additional 60 days to allow for
filing of a patent application. In the event that issues arise regarding scientific integrity or
regulatory compliance, the sponsor will review these issues with the investigator. The sponsor will
not mandate modifications to scientific content and does not have the right to suppress information.
For multicenter study designs and sub-study approaches, secondary results generally should not
be published before the primary endpoints of a study have been published. Similarly, investigators
will recognize the integrity of a multicenter study by not submitting for publication data derived
from the individual study site until the combined results from the completed study have been
submitted for publication, within 18 months after the study end date,or the sponsor confirms there
will be no multicenter study publication. Authorship of publications resulting from this study will
be based on the guidelines on authorship, such as those described in the ICMJE Recommendations
for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals, which
state that the named authors must have made a significant contribution to the conception or design
of the work; or the acquisition, analysis, or interpretation of the data for the work; and drafted the
work or revised it critically for important intellectual content; and given final approval of the
version to be published; and agreed to be accountable for all aspects of the work in ensuring that
questions related to the accuracy or integrity of any part of the work are appropriately investigated
and resolved.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as required
by law. The disclosure of the final study results will be performed after the end of study in order
to ensure the statistical analyses are relevant.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
65
Status: Approved,Date: 26 November 2021
10.3.8. 
Data Quality Assurance
Data Quality Assurance/Quality Control
Steps to be taken to ensure the accuracy and reliability of data include the selection of qualified
investigators and appropriate study sites, review of protocol procedures with the investigator and
study-site personnel before the study, and periodic monitoring visits by the sponsor. Written
instructions will be provided for collection, handling, storage, and shipment of samples.
Guidelines for eCRF completion will be provided and reviewed with study-site personnel before
the start of the study. The sponsor may review the eCRF for accuracy and completeness during
on-site monitoring visits and after transmission to the sponsor; any discrepancies will be resolved
with the investigator or designee, as appropriate. After upload of the data into the study database
they will be verified for accuracy and consistency with the data sources.
10.3.9. 
Case Report Form Completion
Case report forms are prepared and provided by the sponsor for each participant in electronic
format. All eCRF entries, corrections, and alterations must be made by the investigator or
authorized study-site personnel. The investigator must verify that all data entries in the eCRF are
accurate and correct.
The study data will be transcribed by study-site personnel from the source documents onto an
eCRF, if applicable. Study-specific data will be transmitted in a secure manner to the sponsor.
Worksheets may be used for the capture of some data to facilitate completion of the eCRF. Any
such worksheets will become part of the participant’s source documents. Data must be entered into
the eCRF in English. The eCRF must be completed as soon as possible after a participant visit and
the forms should be available for review at the next scheduled monitoring visit.
If necessary, queries will be generated in the eDC tool. If corrections to an eCRF are needed after
the initial entry into the eCRF, this can be done in either of the following ways:
 Investigator and study-site personnel can make corrections in the eDC tool at their own
initiative or as a response to an auto query (generated by the eDC tool).
 Sponsor or sponsor delegate can generate a query for resolution by the investigator and study-
site personnel.
10.3.10. 
Source Documents
At a minimum, source documents consistent in the type and level of detail with that commonly
recorded at the study site as a basis for standard medical care must be available for the following:
participant identification, eligibility, and study identification; study discussion and date of signed
informed consent; dates of visits; results of safety and immunogenicity parameters as required by
the protocol; record of all AEs and follow-up of AEs; concomitant medication; vaccine
receipt/dispensing/return records; study vaccine administration information; and date of study

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
66
Status: Approved,Date: 26 November 2021
completion and reason for early discontinuation of study vaccination or withdrawal from the study,
if applicable.
The author of an entry in the source documents should be identifiable.
The participant diary used to collect information regarding solicited signs and symptoms after
vaccination will be considered source data.
Specific details required as source data for the study and source data collection methods will be
reviewed with the investigator before the study and will be described in the monitoring guidelines
(or other equivalent document).
An eSource system may be utilized, which contains data traditionally maintained in a hospital or
clinic record to document medical care (eg, electronic source documents) as well as the clinical
study-specific data fields as determined by the protocol. This data is electronically extracted for
use by the sponsor. If eSource is utilized, references made to the eCRF in the protocol include the
eSource system but information collected through eSource may not be limited to that found in the
eCRF. Data in the eSource system may be considered source documentation.
10.3.11. 
Monitoring
The sponsor will use a combination of monitoring techniques (central, remote, or on-site
monitoring)to monitor this study.
The sponsor will perform on-site monitoring visits as frequently as necessary. The monitor will
record dates of the visits in a study site visit log that will be kept at the study site. The first post-
initiation visit will be made as soon as possible after enrollment has begun. At these visits, the
monitor may compare data entered into the eCRF with the source documents (eg,hospital/
clinic/physician’s office medical records); a sample may be reviewed. The nature and location of
all source documents will be identified to ensure that all sources of original data required to
complete the eCRF are known to the sponsor and study-site personnel and are accessible for
verification by the sponsor study-site contact. If electronic records are maintained at the study site,
the method of verification must be discussed with the study-site personnel.
Direct access to source documents (medical records) must be allowed for the purpose of verifying
that the recorded data are consistent with the original source data. Findings from this review will
be discussed with the study-site personnel. The sponsor expects that, during monitoring visits, the
relevant study-site personnel will be available, the source documents will be accessible, and a
suitable environment will be provided for review of study-related documents. The monitor will
meet with the investigator on a regular basis during the study to provide feedback on the study
conduct.
In addition to on-site monitoring visits, remote contacts can occur. It is expected that during these
remote contacts, study-site personnel will be available to provide an update on the progress of the
study at the site.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
67
Status: Approved,Date: 26 November 2021
Central monitoring will take place for data identified by the sponsor as requiring central review.
10.3.12. 
On-Site Audits
Representatives of the sponsor’s clinical quality assurance department may visit the study site at
any time during or after completion of the study to conduct an audit of the study in compliance
with regulatory guidelines and company policy. These audits will require access to all study
records, including source documents, for inspection. Participant privacy must, however, be
respected. The investigator and study-site personnel are responsible for being present and available
for consultation during routinely scheduled study-site audit visits conducted by the sponsor or its
designees.
Similar auditing procedures may also be conducted by agents of any regulatory body, either as part
of a national GCP compliance program or to review the results of this study in support of a
regulatory submission. The investigator should immediately notify the sponsor if they have been
contacted by a regulatory agency concerning an upcoming inspection.
10.3.13. 
Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRF
and all source documents that support the data collected from each participant, as well as all study
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a Clinical
Trial, and all study documents as specified by the applicable regulatory requirement(s). The
investigator/institution will take measures to prevent accidental or premature destruction of these
documents.
Essential documents must be retained until at least 2 years after the last approval of a marketing
application in an ICH region and until there are no pending or contemplated marketing applications
in an ICH region or until at least 2 years have elapsed since the formal discontinuation of clinical
development of the investigational product. These documents will be retained for a longer period
if required by the applicable regulatory requirements or by an agreement with the sponsor. It is the
responsibility of the sponsor to inform the investigator/institution as to when these documents no
longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the
responsibility of keeping the study records, custody must be transferred to a person who will accept
the responsibility. The sponsor must be notified in writing of the name and address of the new
custodian. Under no circumstance shall the investigator relocate or dispose of any study documents
before having obtained written approval from the sponsor.
If it becomes necessary for the sponsor or the appropriate regulatory authority to review any
documentation relating to this study, the investigator/institution must permit access to such reports.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
68
Status: Approved,Date: 26 November 2021
10.3.14. 
Study and Site Start and Closure
First Act of Recruitment
The first participant screened is considered the first act of recruitment and it becomes the study
start date.
Study/Site Termination
The sponsor reserves the right to close the study site or terminate the study at any time for any
reason at the sole discretion of the sponsor. Study sites will be closed upon study completion. A
study site is considered closed when all required documents and study supplies have been collected
and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time, provided there is reasonable cause and
sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a study site by the sponsor or investigator may include but are not
limited to:
 Failure of the investigator to comply with the protocol, the requirements of the IEC/IRB or
local health authorities, the sponsor’s procedures, or GCP guidelines
 Inadequate recruitment of participants by the investigator
 Discontinuation of further study vaccine development

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
69
Status: Approved,Date: 26 November 2021
10.4. Appendix 4: Toxicity Grading Scale
Adapted from the FDA Guidance document “Toxicity Grading Scale for Healthy Adult and
Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials” (September 2007) (FDA
2007)
A: Tables for Clinical Abnormalities
Local Reaction to 
Injectable Product 
Mild (Grade 1) 
Moderate (Grade 2) Severe (Grade 3) 
Potentially Life
Threatening
(Grade 4)
Pain/Tenderness# 
Aware of symptoms 
but easily tolerated; 
Does not interfere 
with activity; 
Discomfort only to 
touch  
Notable symptoms; 
Requires modification 
in activity or use of 
medications; 
Discomfort with 
movement 
Incapacitating 
symptoms; 
Inability to do work, 
school, or usual 
activities; 
Use of narcotic pain
reliever
Hospitalization;
Pain/tenderness
causing inability to
perform basic
self-care function
Erythema# 
25 –50 mm  
51 –100 mm  
> 100 mm  
Hospitalization;
Necrosis or
exfoliative dermatitis
Swelling# 
25 –50 mm  
51 –100 mm  
> 100 mm  
Hospitalization;
Necrosis
# Revised by the sponsor.
Vital Signs* 
Mild (Grade 1) 
Moderate (Grade 2) Severe (Grade 3) 
Potentially Life
Threatening
(Grade 4)
Fever (°C)** 
           (°F)** 
38.0 –38.4 
100.4 –101.1 
38.5 –38.9 
101.2 –102.0 
39.0 –40.0 
102.1 –104.0 
> 40 
> 104.0
Tachycardia - beats 
per minute 
101 –115 
116 –130 
> 130 
Hospitalization for
arrhythmia#
Bradycardia - beats 
per minute*** 
50 –54 
45 –49 
< 45 
Hospitalization for
arrhythmia#
Hypertension 
(systolic) - mm Hg 
141 –150 
151 –160# 
> 160# 
Hospitalization for
malignant
hypertension#
Hypertension 
(diastolic) - mm Hg 
91 –95 
96 –100 
> 100 
Hospitalization for
malignant
hypertension#
Hypotension 
(systolic) - mm Hg 
85 –89 
80 –84 
< 80 
Hospitalization for
hypotensive shock#
Respiratory rate - 
breaths per minute
17 –20 
21 –25 
> 25 
Intubation
* 
Participant should be at rest for all vital sign measurements.
** 
For oral temperature: no recent hot or cold beverages or smoking.
*** When resting heart rate is between 60 –100 beats per minute. Use clinical judgment when characterizing
bradycardia among some healthy participant populations,for example,conditioned athletes.
# 
Revised by the sponsor.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
70
Status: Approved,Date: 26 November 2021
Systemic (General) Mild (Grade 1) 
Moderate (Grade 2) Severe (Grade 3) 
Potentially Life
Threatening
(Grade 4)
Vomiting# 
No interference 
with activity or 
1-2 episodes/24 hours 
Some interference 
with activity or 
> 2 episodes/24 hours 
Prevents daily  
activity, requires 
outpatient IV
hydration
Hospitalization;
Hypotensive shock
Nausea# 
Minimal symptoms; 
causes minimal or no 
interference with 
work, school, or 
self-care activities 
Notable symptoms; 
Requires modification 
in activity or use of 
medications; 
Does NOT result in 
loss of work, school, 
or cancellation of 
social activities
Incapacitating 
symptoms; 
Requires bed rest 
and/or results in loss 
of work, school, or
cancellation of social
activities
Hospitalization;
Inability to perform
basic self-care
functions
Diarrhea# 
2 –3 loose stools or 
< 400 gms/24 hours 
4 –5 stools or 
400 –800 gms/24 
hours 
6 or more watery  
stools or 
> 800 gms/24 hours 
or oral rehydration 
necessary
Hospitalization;
Hypotensive shock
OR IV fluid
replacement indicated
Headache# 
Minimal symptoms;
causes minimal or no
interference with
work, school, or
self-care activities
Notable symptoms; 
Requires modification 
in activity or use of 
medications; 
Does NOT result in 
loss of work, school, 
or cancellation of 
social activities 
Incapacitating
symptoms;
Requires bed rest
and/or results in loss
of work, school, or
cancellation of social
activities;
Use of narcotic pain
reliever
Hospitalization;
Inability to perform
basic self-care
functions
Fatigue# 
Minimal symptoms;
causes minimal or no
interference with
work, school, or
self-care activities
Notable symptoms; 
Requires modification 
in activity or use of 
medications; 
Does NOT result in 
loss ofwork, school, 
or cancellation of 
social activities 
Incapacitating
symptoms;
Requires bed rest
and/or results in loss
of work, school, or
cancellation of social
activities;
Use of narcotic pain
reliever
Hospitalization;
Inability to perform
basic self-care
functions
Myalgia# 
Minimal symptoms;
causes minimal or no
interference with
work, school, or
self-care activities
Notable symptoms; 
Requires modification 
in activity or use of 
medications; 
Does NOT result in 
loss of work, school, 
or cancellation of 
social activities 
Incapacitating
symptoms;
Requires bed rest
and/or results in loss
of work, school, or
cancellation of social
activities;
Use of narcotic pain
reliever
Hospitalization;
Inability to perform
basic self-care
functions
# Revised by the sponsor.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
71
Status: Approved,Date: 26 November 2021
Systemic Illness 
Mild (Grade 1) 
Moderate (Grade 2) Severe (Grade 3) 
Potentially Life
Threatening
(Grade 4)
Illness or clinical 
adverse 
event (as defined 
according to 
applicable
regulations)
No interference with  
activity  
Some interference 
with activity not 
requiring medical 
intervention 
Prevents daily  
activity and
requires medical
intervention
Hospitalization#
# Revised by the sponsor.
B: Tables for Laboratory Abnormalities
The laboratory values provided in the tables below serve as guidelines and are dependent upon
institutional normal parameters. Institutional normal reference ranges should be provided to
demonstrate that they are appropriate.
Serum * 
Mild 
(Grade 1) 
Moderate 
(Grade 2) 
Severe 
(Grade 3) 
Potentially Life
Threatening
(Grade 4)**
Sodium –Hyponatremia mEq/L 
132 –134 
130 –131 
125 –129 
< 125
Sodium –Hypernatremia mEq/L 
144 –145 
146 –147 
148 –150 
> 150
Potassium –Hyperkalemia mEq/L 
5.1 –5.2 
5.3 –5.4 
5.5 –5.6 
> 5.6
Potassium –Hypokalemia mEq/L 
3.5 –3.6 
3.3 –3.4 
3.1 –3.2 
< 3.1
Glucose –Hypoglycemia mg/dL 
65 –69 
55 –64 
45 –54 
< 45
Glucose –Hyperglycemia 
  Fasting mg/dL 
  Random –mg/dL 
100 –110 
110 –125 
111 –125 
126 –200 
>125 
> 200 
Insulin
requirements or
hyperosmolar
coma
Blood Urea Nitrogen  
BUN mg/dL
23 –26 
27 –31 
> 31 
Requires dialysis
Creatinine –mg/dL 
1.5 –1.7 
1.8 –2.0 
2.1 –2.5 
> 2.5 or requires
dialysis
Calcium –hypocalcemia mg/dL 
8.0 –8.4 
7.5 –7.9 
7.0 –7.4 
< 7.0
Calcium –hypercalcemia mg/dL 
10.5 –11.0 
11.1 –11.5 
11.6 –12.0 
> 12.0
Magnesium –hypomagnesemia mg/dL 
1.3 –1.5 
1.1 –1.2 
0.9 –1.0 
< 0.9
Phosphorous –hypophosphatemia mg/dL 2.3 –2.5 
2.0 –2.2 
1.6 –1.9 
< 1.6
CPK –mg/dL 
1.25 –1.5 x  
ULN***
1.6 –3.0 x ULN  3.1 –10 x ULN  
> 10 x ULN
Albumin –Hypoalbuminemia g/dL 
2.8 –3.1 
2.5 –2.7 
< 2.5 
--
Total Protein –Hypoproteinemia g/dL 
5.5 –6.0 
5.0 –5.4 
< 5.0 
--
Alkaline phosphate – 
increase by factor
1.1 –2.0 x ULN  2.1 –3.0 x ULN  3.1 –10 x ULN  > 10 x ULN
Liver Function Tests –ALT,AST  
increase by factor
1.1 –2.5 x ULN  2.6 –5.0 x ULN  5.1 –10 x ULN  > 10 x ULN
Bilirubin –when accompanied 
by any increase in Liver Function Test 
increase by factor
1.1 –1.25 x 
ULN  
1.26 –1.5 x 
ULN  
1.51 –1.75 x 
ULN
> 1.75 x ULN
Bilirubin –when Liver Function Test 
is normal; increase by factor
1.1 –1.5 x ULN  1.6 –2.0 x ULN  2.0 –3.0 x ULN  > 3.0 x ULN

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
72
Status: Approved,Date: 26 November 2021
Serum * 
Mild 
(Grade 1) 
Moderate 
(Grade 2) 
Severe 
(Grade 3) 
Potentially Life
Threatening
(Grade 4)**
Cholesterol 
201 –210 
211 –225 
> 226 
--
Pancreatic enzymes –amylase,lipase 
1.1 –1.5 x ULN 1.6 –2.0 x ULN 2.1 –5.0 x ULN > 5.0 x ULN
* 
The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal
parameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate.
** The clinical signs or symptoms associated with laboratory abnormalities might result in characterization of the
laboratory abnormalities as potentially life-threatening (Grade 4). For example. a low sodium value that falls
within a Grade 3 parameter (125-129 mE/L) should be recorded as a Grade 4 hyponatremia event ifthe
participant had a new seizure associated with the low sodium value.
*** ULN is the upper limit ofthe normal range.
Hematology* 
Mild 
(Grade 1) 
Moderate 
(Grade 2) 
Severe 
(Grade 3) 
Potentially Life
Threatening
(Grade 4)
Hemoglobin (Female) - gm/dL 
11.0 –12.0 
9.5 –10.9 
8.0 –9.4 
< 8.0
Hemoglobin (Female) 
change from baseline value - gm/dL 
Any decrease – 
1.5
1.6 –2.0 
2.1 –5.0 
> 5.0
Hemoglobin (Male) - gm/dL 
12.5 –13.5 
10.5 –12.4 
8.5 –10.4 
< 8.5
Hemoglobin (Male) 
change from baseline value - gm/dL 
Any decrease – 
1.5
1.6 –2.0 
2.1 –5.0 
> 5.0
WBC Increase - cell/mm3 
10,800 –15,000 15,001 –20,000 
20,001 –25, 000 > 25,000
WBC Decrease - cell/mm3 
2,500 –3,500 
1,500 –2,499 
1,000 –1,499 
< 1,000
Lymphocytes Decrease - cell/mm3 
750 –1,000 
500 –749 
250 –499 
< 250
Neutrophils Decrease - cell/mm3 
1,500 –2,000 
1,000 –1,499 
500 –999 
< 500
Eosinophils - cell/mm3 
650 –1500 
1501 –5000 
> 5000 
Hypereosinophilic
Platelets Decreased - cell/mm3 
125,000 – 
140,000
100,000 –124,000 25,000 –99,000 
< 25,000
PT –increase by factor 
(prothrombin time) 
1.0 –1.10 x  
ULN**
1.11 –1.20 x ULN  1.21 –1.25 x ULN > 1.25 ULN
PTT –increase by factor 
(partial thromboplastin time)
1.0 –1.2 x ULN  1.21 –1.4 x ULN  1.41 –1.5 x ULN  > 1.5 x ULN
Fibrinogen increase - mg/dL 
400 –500 
501 –600 
> 600 
--
Fibrinogen decrease - mg/dL 
150 –200 
125 –149 
100 –124 
< 100 or associated
with gross bleeding
or disseminated
intravascular
coagulation (DIC)
* The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal
parameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate.
** ULN is the upper limit ofthe normal range.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
73
Status: Approved,Date: 26 November 2021
Urine* 
Mild  
(Grade 1) 
Moderate 
(Grade 2) 
Severe 
(Grade 3) 
Potentially Life
Threatening (Grade 4)
Protein  
Trace 
1+  
2+ 
Hospitalization or
dialysis
Glucose 
Trace 
1+  
2+ 
Hospitalization for
hyperglycemia
Blood (microscopic) – 
red blood cells per 
high power field (RBC/HPF) 
1 –10 
11 –50 
> 50 and/or gross 
blood 
Hospitalization or
packed red blood cells
(PRBC) transfusion
* The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal
parameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
74
Status: Approved,Date: 26 November 2021
10.5. Appendix 5: Study Conduct During aNatural Disaster
GUIDANCE ON STUDY CONDUCT DURING THE COVID-19 PANDEMIC
It is recognized that the Coronavirus Disease 2019 (COVID-19) pandemic may have an impact on
the conduct of this clinical study due to, for example, isolation or quarantine of participants and
study-site personnel; travel restrictions/limited access to public places, including hospitals; study-
site personnel being unavailable, isolated, or reassigned to critical tasks.
The sponsor is providing options for study related participant management in the event of
disruption to the conduct of the study. This guidance does not supersede any local or government
requirements or the clinical judgement of the investigator to protect the health and well-being of
participants and site staff. If, at any time, a participant’s travel to the study site is considered to be
dangerous, study participation may be interrupted, and study follow-up conducted. If it becomes
necessary to discontinue participation in the study, the procedures outlined in the protocol for
discontinuing study intervention will be followed.
If, as a result of the COVID-19 pandemic, scheduled visits cannot be conducted in person at the
study site, they will be performed to the extent possible remotely/virtually or delayed until such
time that on-site visits can be resumed. At each contact, participants will be interviewed to collect
safety data. Key immunogenicity endpoint assessments should be performed if required and as
feasible. Participants will also be questioned regarding general health status to fulfill any physical
examination requirement.
Every effort should be made to adhere to protocol-specified assessments for participants on study
intervention, including follow up. Modifications to protocol-required assessments may be
permitted after consultation with the participant, investigator, and the sponsor. Missed
assessments/visits will be captured in the clinical trial management system for protocol deviations.
Discontinuations ofstudy interventions and withdrawal from the study should be documented with
the prefix “COVID-19-related” in the eCRF.
If a participant has tested positive for COVID-19, the investigator should contact the sponsor’s
responsible medical officer to discuss plans for administration of study intervention, performing
study assessments, and follow-up. Modifications made to the study conduct as a result of the
COVID-19 pandemic should be summarized in the clinical study report.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
75
Status: Approved,Date: 26 November 2021
GUIDANCE SPECIFIC TO THIS PROTOCOL:
Screening and Randomization
 Enrollment of new participants may continue based on the investigator’s assessment of risks
versus benefits, depending on the situation at a particular site, and the ability to monitor
participant safety.
Site Visits
 When site visits are not possible due to local/national guidelines, sites should collect the
assessments via telephone visits or home-based visits, if the participant allows. The actual
visit date and the type of visit (ie, telephone or home-based visit) should be captured in the
eCRF according to the eCRF completion guidelines. Procedures that cannot be performed
during a home-based visit (eg, blood samples), should be excluded. 
Vaccine Administration
 When planning for vaccination visits, local/national or institutional guidelines will be
followed. The study vaccine must be administered by a blinded qualified individual at the
study site. If this is not possible, a solution may be considered in consultation with the sponsor
and taking into consideration participant safety.
Informed Consent Form
 Consenting and re-consenting of participants for the measures taken (including also remote
consenting by phone or video consultation) will be performed as applicable and according to
local guidance for informed consent applicable during the COVID-19 pandemic. The process
is to be documented in the source documents.
Source Data Verification/Monitoring
 In case on-site monitoring visits are not be possible, the site monitor may contact the
investigator to arrange monitoring visits and activities remotely (in accordance with site and
local requirements). Additional on-site monitoring visits may be needed in the future to catch
up on source data verification.
Site Audits
 During the COVID-19 pandemic and at the impacted sites, study site GCP audits with direct
impact/engagement from the investigator and study site personnel would not be conducted in
order to comply with national, local, and/or organizational social distancing restrictions.
Additional quality assurance activities such as remote audits or focused review of study
related documents may take place with limited impact/engagement if possible.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
76
Status: Approved,Date: 26 November 2021
10.6. Appendix 6: Thrombotic Events to be Reported as Potential AESIs
At the time of protocol writing, the list of thrombotic events to be reported to the sponsor as
potential AESIs is provided below. Further guidance may become available on thrombotic events
of interest.
 MedDRA PTs for large vessel thrombosis and embolism
 Aortic embolus, aortic thrombosis, aseptic cavernous sinus thrombosis, brain stem
embolism, brain stem thrombosis, carotid arterial embolus, carotid artery thrombosis,
cavernous sinus thrombosis, cerebral artery thrombosis, cerebral venous sinus
thrombosis, cerebral venous thrombosis, superior sagittal sinus thrombosis, transverse
sinus thrombosis, mesenteric artery embolism, mesenteric artery thrombosis, mesenteric
vein thrombosis, splenic artery thrombosis, splenic embolism, splenic thrombosis,
thrombosis mesenteric vessel, visceral venous thrombosis, hepatic artery embolism,
hepatic artery thrombosis, hepatic vein embolism, hepatic vein thrombosis, portal vein
embolism, portal vein thrombosis, portosplenomesenteric venous thrombosis, splenic
vein thrombosis, spontaneous heparin-induced thrombocytopenia syndrome, femoral
artery embolism, iliac artery embolism, jugular vein embolism, jugular vein thrombosis,
subclavian artery embolism, subclavian vein thrombosis, obstetrical pulmonary
embolism, pulmonary artery thrombosis, pulmonary thrombosis, pulmonary venous
thrombosis, renal artery thrombosis, renal embolism, renal vein embolism, renal vein
thrombosis, brachiocephalic vein thrombosis, vena cava embolism, vena cava
thrombosis, truncus coeliacus thrombosis
 MedDRA PTs for more common thrombotic events
 Axillary vein thrombosis, deep vein thrombosis, pulmonary embolism, MedDRA PTs for
acute myocardial infarction*, MedDRA PTs for stroke*
Source: Shimabukuro T. CDC COVID-19 Vaccine Task Force. Thrombosis with thrombocytopenia syndrome (TTS)
following Janssen COVID-19 vaccine. Advisory Committee on Immunization Practices (ACIP). April 23, 2021.
https://www.cdc.gov/vaccines/acip/meetings/slides-2021-04-23.html.
*Vaccine Adverse Event Reporting System (VAERS) Standard Operating Procedures for COVID-19 (as of 29 January
2021) https://www.cdc.gov/vaccinesafety/pdf/VAERS-v2-SOP.pdf

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
77
Status: Approved,Date: 26 November 2021
10.7. Appendix 7: Protocol Amendment History
The Protocol Amendment Summary of Changes Table for the current amendment is located
directly before the Table of Contents (TOC).
Amendment 1 (23 September 2021)
Overall Rationale for the Amendment: Based on Health Authority feedback, neutralizing
antibody responses (assessed in the virus neutralization assay-A2 [VNA-A2]) will be added as
secondary endpoint to the study to support the conclusions drawn from the comparisons using pre-
F ELISA data as the primary endpoint.
Section Number 
and Name
Description of Change 
Brief Rationale
1.1 Synopsis
3 OBJECTIVES
AND ENDPOINTS
8.1 Immunogenicity
Assessments
9.4.3.2 Secondary
and Exploratory
Endpoint
Adding RSV neutralizing antibody responses
(assessed in the virus neutralization assay-A2
[VNA-A2]) as secondary endpoint.
Note: no change in volume of blood sampling
required.
Following 
Health 
Authority
feedback.
2.2 Background
11 REFERENCES
Experience with Ad26-vectored vaccines was
added.
For alignment with the other
supportive Phase 3 study protocols.
4.2.1 Study-Specific
Ethical Design
Considerations
The results of this study may be made available to
all participants through a plain language summary at
the conclusion of the study according to local
standards/restrictions.
For alignment with the other
supportive Phase 3 study protocols.
2.3.1 Risks Related
to Study
Participation
8.3.5 Pregnancy
In case of pregnancy, postnatal sequelae in the infant
will not be followed-up.
Note: Follow up info regarding the outcome of the
pregnancy of the study participant themselves or of
the partner of the participant will be requested
(upon consent).
According to the current Janssen
SOP  ‘Receipt, Follow-up, and
Reporting of Janssen Medicinal
Product Individual Case Safety
Reports’, follow-up of postnatal
sequelae in the infant is not a
requirement.
The sponsor protocol template is
planned to be modified to reflect this
change.
8.3.1 Time Period
and Frequency for
Collecting AE,
SAE, and AESI
Information
8.3.6.1 Thrombosis
with
Thrombocytopenia
Syndrome
The word ‘symptomatic’ was deleted from the
definition of thrombocytopenia.
Definition of thrombocytopenia is
broadened to include all cases of
thrombocytopenia the investigators
observe (including asymptomatic
thrombocytopenia 
observed 
in
participant’s routine blood test or
blood test performed concomitantly
to any AE/SAE/hospitalization, or
any other) in the period of 6 months
after vaccination; these should be
reported as potential TTS cases
(please refer to Section 8.3.6).
Throughout the
protocol
Minor grammatical, formatting, or spelling changes
were made.
Minor errors were noted

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
78
Status: Approved,Date: 26 November 2021
11. 
REFERENCES
Adenoviral Vaccine Safety Database - Report V6.0. Janssen Vaccines & Prevention B.V. (April 2021).
American Society of Hematology. COVID-19 resources. Thrombosis with Thrombocytopenia Syndrome (also termed
Vaccine-induced 
Thrombotic 
Thrombocytopenia). 
Updated 
6 
May 
2021. 
Available 
at:
https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia. Accessed: 27 April
2021.
Barouch DH, Liu J, Peter L, et al. Characterization of humoral and cellular immune responses elicited by a
recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis.
2013;207:248-256.
Barouch DH, Tomaka FL, Wegmann F, et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised,
double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
Lancet. 2018;392(10143):232-243.
Brighton Collaboration. Updated Proposed Brighton Collaboration process for developing a standard case definition
for study of new clinical syndrome X, as applied to Thrombosis with Thrombocytopenia Syndrome (TTS). 18 May
2021. https://brightoncollaboration.us/wp-content/uploads/2021/05/TTS-Interim-Case-Definition-v10.16.3-May-23-
2021.pdf.Accessed: 02 September 2021.
British Society for Haematology. Guidance produced from the Expert Haematology Panel (EHP) focussed on Covid-
19 
Vaccine 
induced 
Thrombosis 
and 
Thrombocytopenia 
(VITT). 
Available 
at: 
https://b-s-
h.org.uk/media/19530/guidance-version-13-on-mngmt-of-thrombosis-with-thrombocytopenia-occurring-after-c-19-
vaccine 20210407.pdf. Version 1.3; 7 April 2021.  Accessed: 27 April 2021.
Centers for Disease Control and Prevention (CDC). Cases of cerebral venous sinus thrombosis with thrombocytopenia
after receipt of the Johnson & Johnson COVID-19 Vaccine. 13 April 2021. Available at:
https://emergency.cdc.gov/han/2021/han00442.asp. Accessed: 27 April 2021.
de Bree GJ, Heidema J, van Leeuwen EM, et al. Respiratory syncytial virus-specific CD8+ memory T cell responses
in elderly persons. J Infect Dis. 2005;191:1710-1718.
Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and
high-risk adults. N Engl J Med. 2005;352(17):1749-1759.
Falsey AR, Walsh EE. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly
adults. J Infect Dis. 1998;177(2):463-466.
Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev. 2000;13(3):371-384.
Gidudu JK, Walco GA, Taddio A, et al. Immunization site pain: Case definition and guidelines for collection,
analysis, and presentation of immunization safety data. Vaccine. 2012:30;4558-4577.
Investigator’s Brochure: Ad26/protein preF RSV vaccine (JNJ-64400141/JNJ-64213175). Edition 2. Janssen
Vaccines & Prevention B.V. (April 2021).
Janssen Vaccines & Prevention B.V (data on file).
Kohl KS, Walop W, Gidudu J, et al. Swelling at or near injection site: Case definition and guidelines for collection,
analysis and presentation of immunization safety data. Vaccine. 2007:31;5858-5874.
Looney RJ, Falsey AR, Walsh E, Campbell D. Effect of aging on cytokine production in response to respiratory
syncytial virus infection. J Infect Dis. 2002;185:682-685.
Marcy SM, Kohl KS, Dagan R, et al. Fever as an adverse event following immunization: case definition and
guidelines of data collection, analysis, and presentation. Vaccine. 2004;22:551-556.
Milligan ID, Gibani MM, Sewell R, et al. Safety and immunogenicity of novel adenovirus type 26- and modified
vaccinia ankara-vectored ebola vaccines: a randomized clinical trial. JAMA. 2016;315:1610-1623.
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation
and Research. September 2007. Guidance for Industry. Toxicity Grading Scale for Healthy Adult and Adolescent

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
79
Status: Approved,Date: 26 November 2021
Volunteers Enrolled in Preventive Vaccine Clinical Trials. Available at:
https://www.fda.gov/media/73679/download. Accessed 26 January 2021.
U.S. Department of Health and Human Services, Office for Human Research Protections. March 2016. OHRP
Expedited Review Categories (1998). Available at: http://www.hhs.gov/ohrp/regulations-and-
policy/guidance/categories-of-research-expedited-review-procedure-1998/index.html. Accessed 26 January 2021.
US Food and Drug Administration. Conditions for IRB Use of Expedited Review. Federal Register: November 9,
1998 (Volume 63, Number 216). Available at: https://www.hhs.gov/ohrp/news/federal-register-notices/federal-
register-11-09-1998-vol-63-no-216/index.html.
Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus
infection in adults. J Infect Dis. 2004;190:373-378.

VAC18193 (Ad26.RSV.preF [JNJ-64400141]/RSV preF Protein [JNJ-64213175])
Clinical Protocol VAC18193RSV3003 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 
80
Status: Approved,Date: 26 November 2021
INVESTIGATOR AGREEMENT
I have read this protocol and agree that it contains all necessary details for carrying out this study. I will
conduct the study as outlined herein and will complete the study within the time designated.
I will provide copies of the protocol and all pertinent information to all individuals responsible to me who
assist in the conduct of this study. I will discuss this material with them to ensure that they are fully informed
regarding the study vaccine, the conduct of the study, and the obligations of confidentiality.
Coordinating Investigator (where required):
Name (typed or printed):
Institution and Address:
Signature: 
Date:
(Day Month Year)
Principal (Site) Investigator:
Name (typed or printed):
Institution and Address:
Telephone Number:
Signature: 
Date:
(Day Month Year)
Sponsor’s Responsible Medical Officer:
Name (typed or printed): 
Institution: 
Janssen Vaccines & Prevention B.V.
Signature: 
electronic signature appended at the end of the protocol 
Date:
(Day Month Year)
Note: If the address or telephone number of the investigator changes during the study, written notification
will be provided by the investigator to the sponsor, and a protocol amendment will not be required.
PPD

Signature
User 
Date 
Reason
 
26-Nov-2021 
13:09:12
(GMT)
Document Approval
PPD